[10-Q] Applied DNA Sciences, Inc. Quarterly Earnings Report
Applied DNA Sciences, Inc. implemented significant corporate and capital-structure actions in fiscal 2025 while restructuring operations to focus on Therapeutic DNA Production Services. The company completed two reverse stock splits (board-authorized 1-for-50 then 1-for-15, effective June 2, 2025) that adjusted warrant exercise prices and share counts. Since January 2025 the company has reduced headcount by 39%, expects a projected 31% reduction in payroll expenses versus fiscal 2024, and recorded approximately $305,000 and an additional $300,000 in one-time charges related to workforce reductions and ceasing ADCL operations; ADCL is accounted for as discontinued operations.
Revenue and receivables show high customer concentration (e.g., 26%, 23%, 12% in key segments; three customers represented 82% of accounts receivable at June 30, 2025). The company completed an October registered/direct offering with instruments priced at $240.00 (pre-funded warrants exercised during the period) and agreed to placement agent fees of 6% plus warrants. Lease and cash commitments include a $750,000 standby letter of credit and rent expense of $157,320 and $498,416 for the three- and nine-month periods ended June 30, 2025.
Applied DNA Sciences, Inc. ha avviato nel 2025 rilevanti operazioni societarie e modifiche della struttura del capitale, ristrutturando le attivit脿 per concentrarsi sui Servizi di Produzione di DNA Terapeutico. Nel periodo sono stati effettuati due raggruppamenti azionari inversi (autorizzati dal consiglio, 1-contro-50 e poi 1-contro-15, effettivi il 2 giugno 2025) che hanno modificato i prezzi di esercizio dei warrant e il numero di azioni in circolazione. Dal gennaio 2025 la societ脿 ha ridotto l鈥檕rganico del 39%, prevede una riduzione stimata del 31% della spesa per il personale rispetto all鈥檈sercizio 2024 e ha registrato oneri una tantum per circa $305.000 e ulteriori $300.000 legati alle riduzioni del personale e alla cessazione delle attivit脿 di ADCL; ADCL 猫 classificata come attivit脿 cessate.
I ricavi e i crediti mostrano una forte concentrazione clienti (es. 26%, 23%, 12% nei segmenti principali; tre clienti rappresentavano il 82% dei crediti verso clienti al 30 giugno 2025). In ottobre la societ脿 ha completato un鈥檕fferta registrata/diretta con strumenti prezzati a $240.00 (warrant prefinanziati esercitati nel periodo) e ha concordato commissioni per gli agenti collocatori pari al 6% pi霉 warrant. Gli impegni di locazione e liquidit脿 includono una lettera di credito standby di $750.000 e costi di affitto pari a $157.320 e $498.416 rispettivamente per i tre e i nove mesi terminati il 30 giugno 2025.
Applied DNA Sciences, Inc. implement贸 en 2025 importantes medidas corporativas y ajustes en su estructura de capital, reestructurando operaciones para centrarse en los Servicios de Producci贸n de ADN Terap茅utico. La compa帽铆a complet贸 dos consolidaciones de acciones inversas (autorizadas por la junta, 1 por 50 y luego 1 por 15, vigentes el 2 de junio de 2025) que modificaron los precios de ejercicio de los warrants y el n煤mero de acciones. Desde enero de 2025 redujo la plantilla en un 39%, proyecta una reducci贸n del 31% en gastos de n贸mina frente a 2024 y registr贸 cargos 煤nicos por aproximadamente $305,000 y otros $300,000 relacionados con recortes de personal y el cese de las operaciones de ADCL; ADCL se contabiliza como operaciones discontinuadas.
Los ingresos y cuentas por cobrar muestran alta concentraci贸n de clientes (p. ej., 26%, 23%, 12% en segmentos clave; tres clientes representaban el 82% de las cuentas por cobrar al 30 de junio de 2025). En octubre la empresa complet贸 una oferta registrada/directa con instrumentos tasados en $240.00 (warrants prefinanciados ejercidos durante el periodo) y acord贸 comisiones para agentes colocadores del 6% m谩s warrants. Los compromisos de arrendamiento y efectivo incluyen una carta de cr茅dito standby de $750,000 y gastos de alquiler de $157,320 y $498,416 para los periodos de tres y nueve meses terminados el 30 de junio de 2025.
Applied DNA Sciences, Inc.電� 2025 須岅硠鞐半弰鞐� 欷戩殧頃� 旮办梾 氚� 鞛愲掣甑“ 臁办箻毳� 鞁滍枆頃橁碃 鞖挫榿鞚� 鞛惮靹表晿鞐� 旃橂鞖� DNA 靸濎偘 靹滊箘鞀れ棎 欤茧牓頄堨姷雼堧嫟. 鞚挫偓須� 鞀轨澑鞙茧 1雽�50 氚� 鞚挫柎 1雽�15鞚� 霊� 彀 鞐硲頃╈潉 鞕勲(2025雲� 6鞗� 2鞚� 氚滍毃)頃橃棳 鞗岆煱韸� 頄夓偓臧� 氚� 氚滍枆欤检嫕 靾橁皜 臁办爼霅橃棃鞀惦媹雼�. 2025雲� 1鞗� 鞚错泟 鞚鸽牓鞚� 39% 臧愳稌頄堨溂氅� 2024 須岅硠鞐半弰 雽�牍� 旮夓棳牍勳毄鞚� 鞎� 31% 臧愳唽頃� 瓴冹溂搿� 鞝勲頃橁碃, 鞚鸽牓 臧愳稌 氚� ADCL 靷梾 欷戨嫧瓿� 甏�霠暣 鞎� $305,000 氚� 於旉皜 $300,000鞚� 鞚柬殞靹� 牍勳毄鞚� 瓿勳儊頄堨姷雼堧嫟. ADCL鞚� 欷戨嫧鞓侅梾鞙茧 須岅硠 觳橂Μ霅╇媹雼�.
毵れ稖 氚� 毵れ稖毂勱秾鞚� 瓿犼皾 歆戩霃勱皜 雴掛姷雼堧嫟(鞓�: 欤检殧 靹鸽秬 頃鞐愳劀 26%, 23%, 12%; 2025雲� 6鞗� 30鞚� 旮办 靹� 瓿犼皾鞚� 毵れ稖毂勱秾鞚� 82%毳� 彀). 10鞗旍棎電� 雼皜臧� $240.00鞚� 霌彪/歆侅爲 瓿惦毳� 鞕勲(靷爠雮╈瀰 鞗岆煱韸戈皜 旮瓣皠 欷� 頄夓偓霅�)頄堨溂氅�, 氇雽�頄� 靾橃垬耄岆 6% 氚� 鞗岆煱韸鸽ゼ 頃╈潣頄堨姷雼堧嫟. 鞛勲寑 氚� 順勱笀 甏�霠� 鞎届爼鞙茧電� $750,000鞚� 鞀ろ儬氚旍澊 鞁犾毄鞛リ臣 2025雲� 6鞗� 30鞚茧 膦呺霅� 3臧滌洈 氚� 9臧滌洈 旮瓣皠鞐� 雽�頃� 鞛勳皑耄岅皜 臧侁皝 $157,320 氚� $498,416 韽暔霅╇媹雼�.
Applied DNA Sciences, Inc. a mis en place en 2025 d鈥檌mportantes mesures d鈥檈ntreprise et de structure du capital, en restructurant ses op茅rations pour se concentrer sur les services de production d鈥橝DN th茅rapeutique. La soci茅t茅 a r茅alis茅 deux regroupements inverses d鈥檃ctions (autoris茅s par le conseil, 1 pour 50 puis 1 pour 15, effectifs le 2 juin 2025), ajustant les prix d鈥檈xercice des warrants et le nombre d鈥檃ctions. Depuis janvier 2025, l鈥檈ffectif a 茅t茅 r茅duit de 39%, une baisse projet茅e de 31% des d茅penses de paie par rapport 脿 l鈥檈xercice 2024 est attendue, et des charges exceptionnelles d鈥檈nviron $305鈥�000 et suppl茅mentaires $300鈥�000 ont 茅t茅 enregistr茅es li茅es aux suppressions d鈥檈mplois et 脿 l鈥檃rr锚t des activit茅s d鈥橝DCL ; ADCL est comptabilis茅e comme activit茅 abandonn茅e.
Le chiffre d鈥檃ffaires et les cr茅ances montrent une forte concentration client猫le (par ex. 26%, 23%, 12% dans les segments cl茅s ; trois clients repr茅sentaient 82% des cr茅ances au 30 juin 2025). En octobre, la soci茅t茅 a finalis茅 une offre enregistr茅e/directe avec des titres au prix de $240.00 (warrants pr茅financ茅s exerc茅s pendant la p茅riode) et a convenu des commissions d鈥檃gent de placement de 6% plus warrants. Les engagements de bail et de tr茅sorerie incluent une lettre de cr茅dit standby de $750鈥�000 et des loyers de $157鈥�320 et $498鈥�416 pour les p茅riodes de trois et neuf mois closes le 30 juin 2025.
Applied DNA Sciences, Inc. f眉hrte im Gesch盲ftsjahr 2025 bedeutende unternehmens- und kapitalstrukturelle Ma脽nahmen durch und restrukturierte den Betrieb, um sich auf Therapeutische DNA-Produktionsdienstleistungen zu konzentrieren. Das Unternehmen vollzog zwei Reverse-Splits (vorstandsgenehmigt: 1-zu-50 und anschlie脽end 1-zu-15, wirksam zum 2. Juni 2025), wodurch Aus眉bungspreise von Warrants und Aktienanzahl angepasst wurden. Seit Januar 2025 wurde die Belegschaft um 39% reduziert; es wird eine prognostizierte Reduktion der Lohnkosten um 31% gegen眉ber dem Gesch盲ftsjahr 2024 erwartet. Einmalaufwendungen in H枚he von etwa $305.000 und zus盲tzlich $300.000 wurden im Zusammenhang mit Personalabbau und der Einstellung der ADCL-Aktivit盲ten verbucht; ADCL wird als aufgegebene Gesch盲ftst盲tigkeit gef眉hrt.
Umsatz und Forderungen weisen eine hohe Kundenkonzentration auf (z. B. 26%, 23%, 12% in Schl眉sselsegmenten; drei Kunden stellten zum 30. Juni 2025 82% der Forderungen aus Lieferungen und Leistungen). Im Oktober schloss das Unternehmen ein registriertes/direktes Angebot mit Instrumenten zum Preis von $240.00 ab (vorausfinanzierte Warrants w盲hrend des Zeitraums ausge眉bt) und vereinbarte Platzierungsprovisionen von 6% zuz眉glich Warrants. Zu Miet- und Liquidit盲tsverpflichtungen geh枚ren ein Standby-Akkreditiv von $750.000 sowie Mietaufwendungen von $157.320 und $498.416 f眉r die drei- bzw. neunmonatigen Perioden zum 30. Juni 2025.
- Material cost reductions underway: 39% headcount reduction since Jan 2025 and projected 31% payroll expense reduction versus fiscal 2024
- Capital raised via October offering with pre-funded warrants fully exercised, providing financing at $240.00 per unit
- Proprietary technology (LineaDNA, LineaRNAP, LineaIVT) positioned to enable faster, purer DNA/mRNA template production versus plasmid methods
- Available equity under 2020 Equity Incentive Plan: 200,355 shares available
- High customer concentration: three customers = 82% of accounts receivable at June 30, 2025, and several customers account for large shares of revenue by segment
- One-time restructuring charges: ~ $305,000 and additional ~$300,000 related to workforce reduction and ceasing ADCL operations; ADCL treated as discontinued operations
- Complex warrant dilution risks: multiple warrant classes include price-reset mechanisms, floors, and adjustments triggered by reverse splits that may dilute common shareholders
- Liquidity and lease commitments: $750,000 standby letter of credit and significant rent expense ($157,320 three months; $498,416 nine months) constrain cash resources
Insights
TL;DR: Company is restructuring to conserve cash but faces concentrated revenue sources and dilution/complex warrant structures that can pressure minority holders.
Applied DNA is cutting costs materially via workforce reductions (39% headcount reduction since January 2025) and expects ongoing payroll savings (projected 31% annual reduction). These actions produced one-time charges totaling roughly $605,000 across reported items. The October capital transactions at $240 per unit and pre-funded warrant exercises provide near-term financing but introduce complex warrant reset mechanics and potential dilution. High customer concentration (three customers = 82% of AR) increases revenue risk. Lease obligations, a $750,000 letter of credit, and sizable rent expense in the period further constrain liquidity.
TL;DR: Board actions (reverse splits, warrant amendments, change in capital structure) are significant but carry governance and shareholder-liquidity trade-offs.
The Board approved two reverse splits and amended warrant terms including floors (May 2024 warrants floor of $150) and price-reset provisions; these materially changed instrument economics and could affect shareholder dilution and market liquidity. Placement agent compensation (6% cash fee and placement warrants) is standard for small raises but noteworthy given the company鈥檚 concentrated investor base and trading liquidity. Leadership compensation and a temporary CEO salary reduction to $340,000 indicate internal cost discipline, balanced against separation payments and continued need for financing described in the filing.
Applied DNA Sciences, Inc. ha avviato nel 2025 rilevanti operazioni societarie e modifiche della struttura del capitale, ristrutturando le attivit脿 per concentrarsi sui Servizi di Produzione di DNA Terapeutico. Nel periodo sono stati effettuati due raggruppamenti azionari inversi (autorizzati dal consiglio, 1-contro-50 e poi 1-contro-15, effettivi il 2 giugno 2025) che hanno modificato i prezzi di esercizio dei warrant e il numero di azioni in circolazione. Dal gennaio 2025 la societ脿 ha ridotto l鈥檕rganico del 39%, prevede una riduzione stimata del 31% della spesa per il personale rispetto all鈥檈sercizio 2024 e ha registrato oneri una tantum per circa $305.000 e ulteriori $300.000 legati alle riduzioni del personale e alla cessazione delle attivit脿 di ADCL; ADCL 猫 classificata come attivit脿 cessate.
I ricavi e i crediti mostrano una forte concentrazione clienti (es. 26%, 23%, 12% nei segmenti principali; tre clienti rappresentavano il 82% dei crediti verso clienti al 30 giugno 2025). In ottobre la societ脿 ha completato un鈥檕fferta registrata/diretta con strumenti prezzati a $240.00 (warrant prefinanziati esercitati nel periodo) e ha concordato commissioni per gli agenti collocatori pari al 6% pi霉 warrant. Gli impegni di locazione e liquidit脿 includono una lettera di credito standby di $750.000 e costi di affitto pari a $157.320 e $498.416 rispettivamente per i tre e i nove mesi terminati il 30 giugno 2025.
Applied DNA Sciences, Inc. implement贸 en 2025 importantes medidas corporativas y ajustes en su estructura de capital, reestructurando operaciones para centrarse en los Servicios de Producci贸n de ADN Terap茅utico. La compa帽铆a complet贸 dos consolidaciones de acciones inversas (autorizadas por la junta, 1 por 50 y luego 1 por 15, vigentes el 2 de junio de 2025) que modificaron los precios de ejercicio de los warrants y el n煤mero de acciones. Desde enero de 2025 redujo la plantilla en un 39%, proyecta una reducci贸n del 31% en gastos de n贸mina frente a 2024 y registr贸 cargos 煤nicos por aproximadamente $305,000 y otros $300,000 relacionados con recortes de personal y el cese de las operaciones de ADCL; ADCL se contabiliza como operaciones discontinuadas.
Los ingresos y cuentas por cobrar muestran alta concentraci贸n de clientes (p. ej., 26%, 23%, 12% en segmentos clave; tres clientes representaban el 82% de las cuentas por cobrar al 30 de junio de 2025). En octubre la empresa complet贸 una oferta registrada/directa con instrumentos tasados en $240.00 (warrants prefinanciados ejercidos durante el periodo) y acord贸 comisiones para agentes colocadores del 6% m谩s warrants. Los compromisos de arrendamiento y efectivo incluyen una carta de cr茅dito standby de $750,000 y gastos de alquiler de $157,320 y $498,416 para los periodos de tres y nueve meses terminados el 30 de junio de 2025.
Applied DNA Sciences, Inc.電� 2025 須岅硠鞐半弰鞐� 欷戩殧頃� 旮办梾 氚� 鞛愲掣甑“ 臁办箻毳� 鞁滍枆頃橁碃 鞖挫榿鞚� 鞛惮靹表晿鞐� 旃橂鞖� DNA 靸濎偘 靹滊箘鞀れ棎 欤茧牓頄堨姷雼堧嫟. 鞚挫偓須� 鞀轨澑鞙茧 1雽�50 氚� 鞚挫柎 1雽�15鞚� 霊� 彀 鞐硲頃╈潉 鞕勲(2025雲� 6鞗� 2鞚� 氚滍毃)頃橃棳 鞗岆煱韸� 頄夓偓臧� 氚� 氚滍枆欤检嫕 靾橁皜 臁办爼霅橃棃鞀惦媹雼�. 2025雲� 1鞗� 鞚错泟 鞚鸽牓鞚� 39% 臧愳稌頄堨溂氅� 2024 須岅硠鞐半弰 雽�牍� 旮夓棳牍勳毄鞚� 鞎� 31% 臧愳唽頃� 瓴冹溂搿� 鞝勲頃橁碃, 鞚鸽牓 臧愳稌 氚� ADCL 靷梾 欷戨嫧瓿� 甏�霠暣 鞎� $305,000 氚� 於旉皜 $300,000鞚� 鞚柬殞靹� 牍勳毄鞚� 瓿勳儊頄堨姷雼堧嫟. ADCL鞚� 欷戨嫧鞓侅梾鞙茧 須岅硠 觳橂Μ霅╇媹雼�.
毵れ稖 氚� 毵れ稖毂勱秾鞚� 瓿犼皾 歆戩霃勱皜 雴掛姷雼堧嫟(鞓�: 欤检殧 靹鸽秬 頃鞐愳劀 26%, 23%, 12%; 2025雲� 6鞗� 30鞚� 旮办 靹� 瓿犼皾鞚� 毵れ稖毂勱秾鞚� 82%毳� 彀). 10鞗旍棎電� 雼皜臧� $240.00鞚� 霌彪/歆侅爲 瓿惦毳� 鞕勲(靷爠雮╈瀰 鞗岆煱韸戈皜 旮瓣皠 欷� 頄夓偓霅�)頄堨溂氅�, 氇雽�頄� 靾橃垬耄岆 6% 氚� 鞗岆煱韸鸽ゼ 頃╈潣頄堨姷雼堧嫟. 鞛勲寑 氚� 順勱笀 甏�霠� 鞎届爼鞙茧電� $750,000鞚� 鞀ろ儬氚旍澊 鞁犾毄鞛リ臣 2025雲� 6鞗� 30鞚茧 膦呺霅� 3臧滌洈 氚� 9臧滌洈 旮瓣皠鞐� 雽�頃� 鞛勳皑耄岅皜 臧侁皝 $157,320 氚� $498,416 韽暔霅╇媹雼�.
Applied DNA Sciences, Inc. a mis en place en 2025 d鈥檌mportantes mesures d鈥檈ntreprise et de structure du capital, en restructurant ses op茅rations pour se concentrer sur les services de production d鈥橝DN th茅rapeutique. La soci茅t茅 a r茅alis茅 deux regroupements inverses d鈥檃ctions (autoris茅s par le conseil, 1 pour 50 puis 1 pour 15, effectifs le 2 juin 2025), ajustant les prix d鈥檈xercice des warrants et le nombre d鈥檃ctions. Depuis janvier 2025, l鈥檈ffectif a 茅t茅 r茅duit de 39%, une baisse projet茅e de 31% des d茅penses de paie par rapport 脿 l鈥檈xercice 2024 est attendue, et des charges exceptionnelles d鈥檈nviron $305鈥�000 et suppl茅mentaires $300鈥�000 ont 茅t茅 enregistr茅es li茅es aux suppressions d鈥檈mplois et 脿 l鈥檃rr锚t des activit茅s d鈥橝DCL ; ADCL est comptabilis茅e comme activit茅 abandonn茅e.
Le chiffre d鈥檃ffaires et les cr茅ances montrent une forte concentration client猫le (par ex. 26%, 23%, 12% dans les segments cl茅s ; trois clients repr茅sentaient 82% des cr茅ances au 30 juin 2025). En octobre, la soci茅t茅 a finalis茅 une offre enregistr茅e/directe avec des titres au prix de $240.00 (warrants pr茅financ茅s exerc茅s pendant la p茅riode) et a convenu des commissions d鈥檃gent de placement de 6% plus warrants. Les engagements de bail et de tr茅sorerie incluent une lettre de cr茅dit standby de $750鈥�000 et des loyers de $157鈥�320 et $498鈥�416 pour les p茅riodes de trois et neuf mois closes le 30 juin 2025.
Applied DNA Sciences, Inc. f眉hrte im Gesch盲ftsjahr 2025 bedeutende unternehmens- und kapitalstrukturelle Ma脽nahmen durch und restrukturierte den Betrieb, um sich auf Therapeutische DNA-Produktionsdienstleistungen zu konzentrieren. Das Unternehmen vollzog zwei Reverse-Splits (vorstandsgenehmigt: 1-zu-50 und anschlie脽end 1-zu-15, wirksam zum 2. Juni 2025), wodurch Aus眉bungspreise von Warrants und Aktienanzahl angepasst wurden. Seit Januar 2025 wurde die Belegschaft um 39% reduziert; es wird eine prognostizierte Reduktion der Lohnkosten um 31% gegen眉ber dem Gesch盲ftsjahr 2024 erwartet. Einmalaufwendungen in H枚he von etwa $305.000 und zus盲tzlich $300.000 wurden im Zusammenhang mit Personalabbau und der Einstellung der ADCL-Aktivit盲ten verbucht; ADCL wird als aufgegebene Gesch盲ftst盲tigkeit gef眉hrt.
Umsatz und Forderungen weisen eine hohe Kundenkonzentration auf (z. B. 26%, 23%, 12% in Schl眉sselsegmenten; drei Kunden stellten zum 30. Juni 2025 82% der Forderungen aus Lieferungen und Leistungen). Im Oktober schloss das Unternehmen ein registriertes/direktes Angebot mit Instrumenten zum Preis von $240.00 ab (vorausfinanzierte Warrants w盲hrend des Zeitraums ausge眉bt) und vereinbarte Platzierungsprovisionen von 6% zuz眉glich Warrants. Zu Miet- und Liquidit盲tsverpflichtungen geh枚ren ein Standby-Akkreditiv von $750.000 sowie Mietaufwendungen von $157.320 und $498.416 f眉r die drei- bzw. neunmonatigen Perioden zum 30. Juni 2025.
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
| |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
OR
| |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number:
Applied DNA Sciences, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of | (I.R.S. Employer |
incorporation or organization) | Identification No.) |
|
|
| |
(Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| | | | |
Title of each class |
| Trading |
| Name of each exchange on which |
| | The |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
☒
Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
☒
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer ☐ | Accelerated filer ☐ |
Smaller reporting company | |
| Emerging Growth Company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
On August 12, 2025, the registrant had
Table of Contents
Applied DNA Sciences, Inc. and Subsidiaries
Form 10-Q for the Quarterly Period Ended June 30, 2025
Table of Contents
|
| Page |
PART I - FINANCIAL INFORMATION | | |
| | |
Item 1 - Condensed Consolidated Financial Statements (unaudited) | | 1 |
| | |
Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations | | 24 |
| | |
Item 3 - Quantitative and Qualitative Disclosures About Market Risk | | 34 |
| | |
Item 4 - Controls and Procedures | | 35 |
| | |
PART II - OTHER INFORMATION | | |
| | |
Item 1 – Legal Proceedings | | 36 |
| | |
Item 1A – Risk Factors | | 36 |
| | |
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds | | 36 |
| | |
Item 3 – Defaults Upon Senior Securities | | 36 |
| | |
Item 4 – Mine Safety Disclosures | | 36 |
| | |
Item 5 – Other Information | | 36 |
| | |
Item 6 – Exhibits | | 37 |
Table of Contents
Part I - Financial Information
Item 1 - Financial Statements
APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
| | | | | | |
|
| June 30, |
| September 30, | ||
| | 2025 | | 2024 | ||
ASSETS | | (unaudited) | | | | |
Current assets: |
| |
|
| |
|
Cash and cash equivalents | | $ | | | $ | |
Accounts receivable, net of allowance for credit losses of $ | |
| | |
| |
Inventories | |
| | |
| |
Prepaid expenses and other current assets | |
| | |
| |
Current assets of discontinued operations | | | | | | |
Total current assets | |
| | |
| |
| | | | | | |
Property and equipment, net | |
| | |
| |
Noncurrent assets of discontinued operations | | | | | | |
Other assets: | |
| | |
| |
Restricted cash | | | | | | |
Intangible assets | | | | | | |
Operating right of use asset | | | | | | |
Total assets | | $ | | | $ | |
| | | | | | |
LIABILITIES AND EQUITY | |
|
| |
|
|
| | | | | | |
Current liabilities: | |
| | |
|
|
Accounts payable and accrued liabilities | | $ | | | $ | |
Operating lease liability, current | | | | | | |
Deferred revenue | |
| | |
| |
Current liabilities of discontinued operations | | | | | | |
Total current liabilities | |
| | |
| |
| | | | | | |
Long term accrued liabilities | |
| | |
| |
Deferred revenue, long term | | | | | | |
Operating lease liability, long term | | | — | | | |
Deferred tax liability, net | | | | | | |
Warrants classified as a liability | | | | | | |
Total liabilities | |
| | |
| |
| | | | | | |
Commitments and contingencies (Note G) | |
|
| |
|
|
| | | | | | |
Applied DNA Sciences, Inc. stockholders’ equity: | |
|
| |
|
|
Preferred stock, par value $ | |
| — | |
| — |
Series A Preferred stock, par value $ | |
| — | |
| — |
Series B Preferred stock, par value $ | |
| — | |
| — |
| | | | | | |
Common stock, par value $ | |
| | |
| |
Additional paid in capital | |
| | |
| |
Accumulated deficit | |
| ( | |
| ( |
Applied DNA Sciences, Inc. stockholders’ equity | |
| | |
| |
Noncontrolling interest | | | ( | | | ( |
Total equity | | | | | | |
| | | | | | |
Total liabilities and equity | | $ | | | $ | |
See the accompanying notes to the unaudited condensed consolidated financial statements
1
Table of Contents
APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
| | | | | | | | | | | | |
| | Three months Ended June 30, | | Nine months Ended June 30, | ||||||||
|
| 2025 |
| 2024 |
| 2025 |
| 2024 | ||||
Revenues |
| |
|
| |
|
| |
|
| |
|
Product revenues | | $ | | | $ | | | $ | | | $ | |
Service revenues | | | | | | | | | | | | |
Total revenues | | | | | | | | | | | | |
| |
| | | | | | | | | | |
Cost of product revenues | | | | | | | | | | | | |
| | | | | | | | | | | | |
Gross profit | | | | | | | | | | | | |
| | | | | | | | | | | | |
Operating expenses: | | | | | | | | | | | | |
Selling, general and administrative | | | | | | | | | | | | |
Research and development | | | | | | | | | | | | |
Total operating expenses | | | | | | | | | | | | |
| | | | | | | | | | | | |
LOSS FROM OPERATIONS | | | ( | | | ( | | | ( | | | ( |
| |
|
| | |
| | | | | | |
Interest income | | | | | | | | | | | | |
Transaction costs allocated to warrant liabilities | | | — | | | — | | | — | | | ( |
Unrealized gain on change in fair value of warrants classified as a liability | | | | | | | | | | | | |
Unrealized loss on change in fair value of warrants classified as a liability - warrant modification | | | — | | | — | | | — | | | ( |
Loss on issuance of warrants | | | — | | | — | | | — | | | ( |
Other expense, net | | | ( | | | ( | | | ( | | | ( |
| |
| | | | | | | | | | |
(Loss) income before provision for income taxes | | | ( | | | | | | ( | | | ( |
| | | | | | | | | | | | |
Provision for income taxes | | | — | | | — | | | — | | | — |
| | | | | | | | | | | | |
Net (loss) income from continuing operations | | $ | ( | | $ | | | $ | ( | | $ | ( |
Net loss from discontinued operations, net of tax | | | ( | | | ( | | | ( | | | ( |
| | | | | | | | | | | | |
NET (LOSS) INCOME | | $ | ( | | $ | | | $ | ( | | $ | ( |
| | | | | | | | | | | | |
Less: Net loss attributable to noncontrolling interest | | | | | | | | | | | | |
NET (LOSS) INCOME attributable to Applied DNA Sciences, Inc. | | $ | ( | | $ | | | $ | ( | | $ | ( |
Deemed dividend related to warrant modifications | | | ( | | | — | | | ( | | | ( |
NET (LOSS) INCOME attributable to common stockholders | | $ | ( | | $ | | | $ | ( | | $ | ( |
| | | | | | | | | | | | |
Net (loss) income per share attributable to common stockholders-basic and diluted from continuing operations | | $ | ( | | $ | | | $ | ( | | $ | ( |
Net loss per share attributable to common stockholders-basic and diluted from discontinued operations | | | ( | | | ( | | | ( | | | ( |
Net (loss) income per share attributable to common stockholders-basic and diluted | | $ | ( | | $ | | | $ | ( | | $ | ( |
| | | | | | | | | | | | |
Weighted average shares outstanding- basic and diluted | |
| | |
| | |
| | |
| |
See the accompanying notes to the unaudited condensed consolidated financial statements
2
Table of Contents
APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
(Unaudited)
| | | | | | | | | | | | | | | | | |
| | Nine-Month Period ended June 30, 2024 | |||||||||||||||
| | | | Common | | Additional | | |
| | | | |||||
| | Common | | Stock | | Paid in | | Accumulated | | Noncontrolling | | | |||||
|
| Shares |
| Amount |
| Capital |
| Deficit |
| Interest |
| Total | |||||
Balance, October 1, 2023 |
| | | $ | | | $ | | | $ | ( | | $ | ( | | $ | |
Exercise of warrants, cashlessly | | — | | | — | | | — | | | — | | | — | | | — |
Stock based compensation expense |
| — | |
| — | |
| | |
| — | | | — | |
| |
Common stock issued in ATM, net of offering costs | | | | | — | | | | | | — | | | — | | | |
Deemed dividend - warrant repricing | | — | | | — | | | | | | ( | | | — | | | — |
Net Loss | | — | | | — | | | — | | | ( | | | ( | | | ( |
Balance December 31, 2023 | | | | | | | | | | | ( | | | ( | | | |
Common stock issued in ATM, net of offering costs | | | | | — | | | | | | — | | | — | | | |
Common stock issued in Registered direct offering, net of offering costs | | | | | — | | | | | | — | | | — | | | |
Stock based compensation expense | | — | | | — | | | | | | — | | | — | | | |
Share issued upon restricted stock vesting | | | | | — | | | — | | | — | | | — | | | — |
Deemed dividend - warrant repricing | | — | | | — | | | | | | ( | | | — | | | — |
Net loss | | — | | | — | | | — | | | ( | | | ( | | | ( |
Balance, March 31, 2024 | | | | $ | | | $ | | | $ | ( | | $ | ( | | $ | ( |
| | | | | | | | | | | | | | | | | |
Common stock and pre-funded warrants issued in public offering, net of offering costs | | | | | | | | | | | — | | | — | | | |
Stock based compensation expense | | — | | | — | | | | | | — | | | — | | | |
Exercise of warrants | | | | | | | | | | | — | | | — | | | |
Adjustment for reverse split | | | | | — | | | — | | | — | | | — | | | — |
Net income | | — | | | — | | | — | | | | | | ( | | | |
Balance, June 30, 2024 | | | | $ | | | $ | | | $ | ( | | $ | ( | | $ | |
3
Table of Contents
| | | | | | | | | | | | | | | | | |
| | Nine-Month Period ended June 30, 2025 | |||||||||||||||
| | | | Common | | Additional | | | | | | | |||||
| | Common | | Stock | | Paid in | | Accumulated | | Noncontrolling | | | |||||
|
| Shares |
| Amount |
| Capital |
| Deficit |
| Interest |
| Total | |||||
Balance, October 1, 2024 |
| | | $ | | | $ | | | $ | ( | | $ | ( | | $ | |
Exercise of warrants | | | | | | | | | | | — | | | — | | | |
Exercise of warrants, cashlessly | | | | | | | | ( | | | — | | | — | | | — |
Stock based compensation expense | | — | | | — | | | | | | — | | | — | | | |
Common stock and pre-funded warrants issued in registered direct offering, net of offering costs | | | | | | | | | | | — | | | — | | | |
Deemed dividend - warrant repricing | | — | | | — | | | | | | ( | | | — | | | — |
Net Loss | | — | | | — | | | — | | | ( | | | ( | | | ( |
Balance December 31, 2024 | | | | | | | | | | | ( | | | ( | | | |
| | | | | | | | | | | | | | | | | |
Exercise of warrants | | | | | | | | | | | — | | | — | | | |
Exercise of warrants, cashlessly | | | | | | | | ( | | | — | | | — | | | — |
Stock based compensation expense | | — | | | — | | | | | | — | | | — | | | |
Deemed dividend - warrant repricing | | — | | | — | | | | | | ( | | | — | | | — |
Adjustment for reverse split | | | | | | | | ( | | | — | | | — | | | — |
Net loss | | — | | | — | | | — | | | ( | | | ( | | | ( |
Balance, March 31, 2025 | | | | $ | | | $ | | | $ | ( | | $ | ( | | $ | |
| | | | | | | | | | | | | | | | | |
Exercise of warrants | | | | | | | | | | | — | | | — | | | |
Exercise of warrants, cashlessly | | | | | | | | ( | | | — | | | — | | | — |
Stock based compensation expense | | — | | | — | | | | | | — | | | — | | | |
Deemed dividend - warrant repricing | | — | | | — | | | | | | ( | | | — | | | — |
Adjustment for reverse split | | | | | | | | ( | | | — | | | — | | | — |
Net loss | | — | | | — | | | — | | | ( | | | ( | | | ( |
Balance, June 30, 2025 | | | | $ | | | $ | | | $ | ( | | $ | ( | | $ | |
See the accompanying notes to the unaudited condensed consolidated financial statements
4
Table of Contents
APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
| | | | | | |
| | Nine Months Ended June 30, | ||||
|
| 2025 |
| 2024 | ||
Cash flows from operating activities: |
| |
|
| |
|
Net loss | | $ | ( | | $ | ( |
Net loss from discontinued operations | | | ( | | | ( |
Net loss from continuing operations | | $ | ( | | $ | ( |
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities from continuing operations: | |
| | |
| |
Depreciation and amortization | |
| | |
| |
Loss on write-off of property and equipment | | | | | | — |
Unrealized gain on change in fair value of warrants classified as a liability | | | ( | | | ( |
Unrealized loss on change in fair value of warrants classified as a liability-warrant modification | | | — | | | |
Transaction costs allocated to warrant liabilities | | | — | | | |
Loss on issuance of warrants | | | — | | | |
Stock-based compensation | |
| | |
| |
Change in provision for bad debts | |
| | |
| — |
Change in operating assets and liabilities: | | | | | | |
Accounts receivable | | | | | | ( |
Inventories | | | | | | ( |
Prepaid expenses, other current assets and deposits | | | | | | ( |
Accounts payable and accrued liabilities | | | ( | | | ( |
Deferred revenue | | | | | | ( |
Net cash used in operating activities from continuing operations | |
| ( | |
| ( |
| | | | | | |
Cash flows from investing activities: | |
| | |
|
|
Purchase of property and equipment | | | ( | | | ( |
Net cash used in investing activities from continuing operations | | | ( | | | ( |
| | | | | | |
Cash flows from financing activities: | | | | | | |
Net proceeds from exercise of warrants | | | | | | |
Net proceeds from issuance of common stock and pre-funded warrants | | | | | | |
Net cash provided by financing activities from continuing operations | | | | | | |
CASH FLOWS FROM DISCONTINUED OPERATIONS | | | | | | |
Cash used in operating activities | | | ( | | | ( |
Cash provided by investing activities | | | | | | |
Net cash used by discontinued operations | | | ( | | | ( |
Net (decrease) increase in cash, cash equivalents and restricted cash | | | ( | | | |
Cash, cash equivalents and restricted cash at beginning of period | | | | | | |
Cash, cash equivalents and restricted cash at end of period | | $ | | | $ | |
Less: cash and cash equivalents of discontinued operations | | $ | ( | | $ | ( |
Cash, cash equivalents and restricted cash of continuing operations at end of period | | $ | | | $ | |
Supplemental Disclosures of Cash Flow Information: | | | | | | |
Cash paid during period for interest | | $ | — | | $ | — |
Cash paid during period for income taxes | | $ | — | | $ | — |
Non-cash investing and financing activities: | | | | | | |
Transaction costs included in accounts payable | | $ | — | | $ | |
Deemed dividend warrant modifications | | $ | | | $ | |
Warrants issued, cashlessly | | $ | | | $ | — |
Property and equipment acquired and included in accounts payable | | $ | — | | $ | |
See the accompanying notes to the unaudited condensed consolidated financial statements
5
Table of Contents
APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES
FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2025
(unaudited)
NOTE A — NATURE OF THE BUSINESS
Applied DNA Sciences, Inc. (“Applied DNA” or the “Company”) is a biotechnology company focused on providing nucleic-acid production solutions for the biopharmaceutical and diagnostics industries. Via our LineaRx, Inc. (“LRx”) subsidiary, the Company’s technologies enable cell-free manufacturing of deoxyribonucleic acid (“DNA”) and ribonucleic acid (“RNA”), which are essential components for a new generation of advanced biotherapeutics, such as gene therapies, adoptive cell therapies, messenger RNA (“mRNA”) therapeutics and DNA vaccines, as well as diagnostic applications (“Therapeutic DNA Production Services”).
Historically, the Company operated in
In addition, on June 30, 2025, the Company announced a further strategic restructuring and realignment of resources to focus exclusively on its nucleic-acid production solutions for pharmaceutical and diagnostic applications. As part of actions undertaken, the Company implemented a workforce reduction of approximately
On March 13, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of its Certificate of Incorporation that effected a one-for-fifty (1:50) reverse stock split of its common stock, par value $
All warrant, option, share, and per share information in the condensed consolidated financial statements gives retroactive effect to the 2025 Reverse Splits. Please see Note E for more information.
6
Table of Contents
APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES
FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2025
(unaudited)
NOTE B — BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES
Interim Financial Statements
The accompanying condensed consolidated financial statements as of June 30, 2025, and for the three and nine-month periods ended June 30, 2025, and 2024 are unaudited. These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and are presented in accordance with the requirements of Regulation S-X of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements.
In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine-month periods ended June 30, 2025 are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, 2025. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the fiscal year ended September 30, 2024 and footnotes thereto included in the Company’s Annual Report on Form 10-K filed with the SEC on December 17, 2024. The condensed consolidated balance sheet as of September 30, 2024 contained herein has been derived from the audited consolidated financial statements as of September 30, 2024 but does not include all disclosures required by GAAP.
Principles of Consolidation
The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, APDN (B.V.I.) Inc., Applied DNA Sciences India Private Limited (which currently has no operations), ADCL (see Discontinued Operations below), Spindle Biotech, Inc., Applied DNA Sciences Europe Limited (which currently has no operations) and its majority-owned subsidiary, LRx. Significant inter-company transactions and balances have been eliminated in consolidation.
Discontinued Operations
The condensed consolidated financial statements separately report discontinued operations and the results of continuing operations (see Note J). All footnotes exclude discontinued operations unless otherwise noted.
Going Concern and Management’s Plan
The Company has recurring net losses. The Company incurred a net loss from continuing operations of $
The Company’s current capital resources include cash and cash equivalents. Historically, the Company has financed its operations principally from the sale of equity and equity-linked securities.
Use of Estimates
The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The most significant estimates include revenue recognition, recoverability of long-lived assets, including the values assigned to intangible assets, fair value calculations for warrants, contingencies, and management’s anticipated liquidity. Management reviews its estimates on a regular basis and the effects of any material revisions are reflected in the consolidated financial statements in the period they are deemed necessary. Accordingly, actual results could differ from those estimates.
7
Table of Contents
APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES
FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2025
(unaudited)
NOTE B — BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES, continued
Revenue Recognition
The Company follows Financial Accounting Standards Board (“FASB”) Accounting Standards Codifications (“ASC”), Revenue Recognition (“ASC 606” or “Topic 606”).
The Company measures revenue at the amounts that reflect the consideration to which it is expected to be entitled in exchange for transferring control of goods and services to customers. The Company recognizes revenue either at the point in time or over the period of time that performance obligations to customers are satisfied. The Company’s contracts with customers may include multiple performance obligations (e.g. DNA products, maintenance, authentication services, research and development services, etc.). For such arrangements, the Company allocates revenues to each performance obligation based on their relative standalone selling price.
Due to the short-term nature of the Company’s current contracts with customers, it has elected to apply the practical expedients under Topic 606 to: (1) expense as incurred, incremental costs of obtaining a contract and (2) not adjust the consideration for the effects of a significant financing component for contracts with an original expected duration of one year or less.
Product Revenues
The Company’s DNA product revenues are accounted for/recognized in accordance with contracts with customers. The Company recognizes revenue upon satisfying its promises to transfer goods or services to customers under the terms of its contracts. These performance obligations are satisfied at the point in time the Company transfers control of the goods to the customer, which in nearly all cases is when title to and risk of loss of the goods transfer to the customer. The timing of transfer of title and risk of loss is dictated by customary or explicitly stated contract terms. The Company invoices customers upon shipment, and its collection terms range, on average, from 30 to 60 days.
Authentication Services
The Company recognizes revenue for authentication services upon satisfying its promises to provide services to customers under the terms of its contracts. These performance obligations are satisfied at the point in time the Company services are complete, which in nearly all cases is when the authentication report is released to the customer.
Research and Development Services
The Company’s revenue from its research and development contracts are accounted for/recognized when the performance obligations per the contract are satisfied. These performance obligations are satisfied at the point in time, either when the Company’s services are complete, or when the Company transfers control of the goods to the customer, which in nearly all cases is when title to and risk of loss of the goods transfer to the customer, or when a report is released to a customer. The timing of transfer of title and risk of loss is dictated by customary or explicitly stated contract terms. The Company invoices customers upon shipment, or completion of the services and its collection terms range, on average, from 30 to 60 days.
Disaggregation of Revenue
The following table presents revenues disaggregated by our business operations and timing of revenue recognition:
| | | | | | |
| | Three Month Period Ended: | ||||
| | June 30, | | June 30, | ||
|
| 2025 |
| 2024 | ||
Research and development services (point-in-time) | | $ | | | $ | |
Product and authentication services (point-in-time): | |
| | |
| |
Supply chain | |
| | |
| |
Large Scale DNA Production | | | | | | |
Total | | $ | | | $ | |
8
Table of Contents
APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES
FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2025
(unaudited)
NOTE B — BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES, continued
Revenue Recognition, continued
| | | | | | |
| | Nine Month Period Ended: | ||||
| | June 30, | | June 30, | ||
|
| 2025 |
| 2024 | ||
Research and development services (point-in-time) | | $ | | | $ | |
Product and authentication services (point-in-time): | | | | | | |
Supply chain | |
| | |
| |
Large Scale DNA Production | |
| | |
| |
Asset marking | | | — | | | |
Total | | $ | | | $ | |
Contract balances
As of June 30, 2025, the Company has entered into contracts with customers for which revenue has not yet been recognized. Consideration received from a customer prior to revenue recognition is recorded to a contract liability and is recognized as revenue when the Company satisfies the related performance obligations under the terms of the contract. The Company’s contract liabilities, which are reported as deferred revenue on the condensed consolidated balance sheet, consist almost entirely of research and development contracts where consideration has been received and the development services have not yet been fully performed.
The opening and closing balances of the Company’s contract balances are as follows:
| | | | | | | | | | | |
| | | | October 1, | | June 30, | | $ | |||
|
| Balance sheet classification |
| 2024 |
| 2025 |
| change | |||
Contract assets | | Accounts receivables | | $ | | | $ | | | $ | ( |
Contract liabilities |
| Deferred revenue | | $ | | | $ | | | $ | ( |
| | | | | | | | | | | |
| | | | October 1, | | September 30, | | $ | |||
|
| Balance sheet classification |
| 2023 |
| 2024 |
| change | |||
Contract assets | | Accounts receivables | | $ | | | $ | | | $ | |
Contract liabilities |
| Deferred revenue | | $ | | | $ | | | $ | ( |
For the three and nine-month periods ended June 30, 2025, the Company recognized $
Cash, Cash Equivalents, and Restricted Cash
For the purpose of the accompanying condensed consolidated financial statements, all highly liquid investments with a maturity of three months or less from when purchased are considered to be cash equivalents. The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the statement of cash flows.
| | | | | | |
|
| June 30, |
| September 30, | ||
| | 2025 | | 2024 | ||
Cash and cash equivalents | | $ | | | $ | |
Restricted cash | |
| | |
| |
Total cash, cash equivalents and restricted cash | | $ | | | $ | |
Inventories
Inventories, which consist primarily of raw materials, work in progress and finished goods, are stated at the lower of cost or net realizable value, with cost determined by using the first-in, first-out (FIFO) method.
9
Table of Contents
APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES
FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2025
(unaudited)
NOTE B — BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES, continued
Net Loss Per Share
The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share. Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period. Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company’s stock options, restricted stock units and warrants.
Securities that could potentially dilute basic net loss per share in the future that were not included in the computation of diluted net loss per share because to do so would have been anti-dilutive for the three and nine-month periods ended June 30, 2025 and 2024 are as follows:
| | | | |
|
| 2025 |
| 2024 |
Warrants | | | | |
Stock options | | | | |
Total | | | | |
Concentrations
Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and cash equivalents with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit. As of June 30, 2025, the Company had cash and cash equivalents of approximately $
The Company’s revenues earned from sale of products and services for the three-month period ended June 30, 2025 included an aggregate of
The Company’s revenues earned from sale of products and services for the three and nine-month periods ended June 30, 2024 included an aggregate of
Warrant Liabilities
The Company evaluates its issued warrants in accordance with ASC 480 “Distinguishing Liabilities from Equity” and ASC 815-40, “Derivatives and Hedging — Contracts in Entity’s Own Equity” and concluded that due to the terms of certain of its warrant agreements, the instruments do not qualify for equity treatment. As such, certain of the Company’s issued warrants were recorded as a liability on the condensed consolidated balance sheet and measured at fair value at inception and at each reporting date in accordance with ASC 820, “Fair Value Measurement”, with changes in fair value recognized in the condensed consolidated statement of operations in the period of change.
10
Table of Contents
APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES
FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2025
(unaudited)
NOTE B — BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES, continued
Segment Reporting
Historically, the Company operated in
Therapeutic DNA Production Services — Segment operations consist of the Company’s nucleic-acid production solutions for the biopharmaceutical and diagnostics industries including LineaDNA, LineaRNAP and LineaIVT.
DNA Tagging and Security Products and Services — Segment operations consist of the manufacture and detection of DNA for industrial supply chains and security services. As discussed above, on February 13, 2025, the Company announced it was exiting its DNA Tagging and Security Products and Services business segment. The Company continues to strategically exit contracts relating to this segment and currently plans to continue to service certain of its existing DNA Tagging and Security Products and Services customer contracts.
The Company evaluates the performance of its segments and allocates resources to them based on revenues and operating income (losses). Operating income (loss) includes intersegment revenues, as well as a charge allocating all corporate headquarters costs. Since each vertical has shared employee resources, payroll and certain other general expenses such as rent, and utilities were allocated based on an estimate by management of the percentage of employee time spent in each vertical. Segment assets are not reported to, or used by, the CODM to allocate resources to, or assess performance of, the segments and therefore, total segment assets have not been disclosed.
Fair Value of Financial Instruments
The valuation techniques utilized are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect internal market assumptions. These two types of inputs create the following fair value hierarchy:
Level 1 — Unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2 — Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related asset or liabilities.
Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of assets or liabilities.
The Company utilizes observable market inputs (quoted market prices) when measuring fair value whenever possible.
The development and determination of the unobservable inputs, as well as the valuation policies and procedures for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s accounting and finance department and are approved by the Chief Financial Officer.
As of June 30, 2025, there were
11
Table of Contents
APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES
FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2025
(unaudited)
NOTE B — BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES, continued
Recent Accounting Standards
In November 2024, the FASB issued Accounting Standards Update (ASU) No. 2024-03, Disaggregation of Income Statement Expenses, that requires public companies to provide additional disclosure of the nature of expenses included in the income statement. This ASU requires disclosure about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. This guidance is effective within annual reporting periods beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application, early adoption is permitted. The Company is currently evaluating the impact of this ASU on its condensed consolidated statement of operations and on its disclosures.
In December 2023, the FASB issued Accounting Standards Update (ASU) No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, that enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The guidance is effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and should be applied prospectively with the option of retrospective application. The Company is currently evaluating the impact of adopting this ASU on its disclosures.
In November 2023, the FASB issued ASU No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure.” The ASU updates reportable segment disclosure requirements, primarily through requiring enhanced disclosures about significant segment expenses and information used to assess segment performance. These disclosures are required quarterly. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024, with early adoption permitted. The Company adopted this ASU as of October 1, 2024 and updated its segment reporting disclosures accordingly for the three and nine-month periods ended June 30, 2025 and 2024.
In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40).” The objective of this update is to simplify the accounting for convertible preferred stock by removing the existing guidance in ASC 470-20, “Debt: Debt with Conversion and Other Options,” that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract. This amendment also further revises the guidance in ASU 260, “Earnings per Share,” to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments in ASU 2020-06 were effective for the Company beginning October 1, 2024. The adoption of ASU 2020-06 did not have a significant impact on the Company’s condensed consolidated financial statements.
NOTE C — INVENTORIES
Inventories consist of the following:
| | | | | | |
| | June 30, | | September 30, | ||
|
| 2025 |
| 2024 | ||
| | (unaudited) | | | | |
Raw materials | | $ | | | $ | |
Work-in-progress | | | | | | |
Finished goods | |
| | |
| |
Total | | $ | | | $ | |
12
Table of Contents
APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES
FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2025
(unaudited)
NOTE D — ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
Accounts payable and accrued liabilities are as follows:
| | | | | | |
| | June 30, | | September 30, | ||
|
| 2025 |
| 2024 | ||
| | (unaudited) | | | | |
Accounts payable | | $ | | | $ | |
Accrued salaries payable | |
| | |
| |
Other accrued expenses | |
| | |
| |
Total | | $ | | | $ | |
Included in accrued salaries and payable is $
NOTE E — CAPITAL STOCK
Reverse Stock Splits
March 2025 Reverse Split
On September 30, 2024, the Company held its annual shareholders’ meeting where its stockholders approved a proposal to grant the Company’s Board of Directors discretionary authority for
The March 2025 Reverse Split was effected as of 12:01 a.m. Eastern Time on March 14, 2025 and combined each fifty shares of the Company’s outstanding common stock into one share of common stock, without any change in the par value per share.
June 2025 Reverse Split
On May 22, 2025, the Company held its annual shareholders’ meeting where its stockholders approved a proposal to grant the Company’s Board of Directors discretionary authority for
The June 2025 Reverse Split was effected as of 12:01 a.m. Eastern Time on June 2, 2025 and combined each fifteen shares of the Company’s outstanding common stock into one share of common stock, without any change in the par value per share.
Moreover, each of the 2025 Reverse Splits correspondingly adjusted: (i) the per share exercise price and the number of shares issuable upon the exercise of all outstanding options; and (ii) the number of shares underlying any of our outstanding warrants by adjusting the conversion ratio for each instrument and increasing the applicable exercise price or conversion price in accordance with the terms of each instrument and based on the reverse stock split ratio.
13
Table of Contents
APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES
FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2025
(unaudited)
NOTE E — CAPITAL STOCK, continued
Registered Direct Offering and Concurrent Private Placement
On October 31, 2024, the Company closed a registered direct offering (the “October Registered Direct Offering”) in which, pursuant to the Securities Purchase Agreement dated October 30, 2024 (the “October Purchase Agreement”), by and between the Company and certain institutional investors (the “October Purchasers”), the Company issued and sold
The Company received net proceeds from the October Offering, after deducting placement agent fees and other offering expenses payable by the Company, of approximately $
The exercisability of the October Series Warrants and the Placement Agent Warrants required approval of the Company’s stockholders, which was obtained at the Company’s annual meeting held on May 22, 2025. Each October Series C Warrant has an exercise price of $
Under the alternate cashless exercise option of the October Series D Warrants, the holder of an October Series D Warrant has the right to receive an aggregate number of shares equal to the product of (x) the aggregate number of shares of the Company’s common stock that would be issuable upon a cash exercise of the October Series D Warrant and (y)
On March 14, 2025, the Company completed the March 2025 Reverse Stock Split. As a result, the exercise price reset mechanism was triggered, which resulted in the number of shares of common stock issuable upon exercise of the October Series D Warrants increasing from
14
Table of Contents
APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES
FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2025
(unaudited)
NOTE E — CAPITAL STOCK, continued
Registered Direct Offering and Concurrent Private Placement, continued
The October Series Warrants and the Placement Agent Warrants are not registered under the Securities Act of 1933, as amended (the “Securities Act”). The October Series Warrants and the Placement Agent Warrants were issued, and the shares of the Company’s common stock issuable upon exercise thereof will be issued (unless an effective registration statement is available), in reliance on the exemptions from registration provided by Section 4(a)(2) under the Securities Act and Regulation D promulgated thereunder, for transactions not involving a public offering.
Pursuant to the October Purchase Agreement, within
In the event of any fundamental transaction, as described in the October Warrants and generally including any merger with or into another entity, sale of all or substantially all of the Company’s assets, tender offer or exchange offer, reclassification of the shares of common stock, or the acquisition of greater than 50% of the Company’s then outstanding shares of common stock by a person or persons, subject to certain exceptions, then upon any subsequent exercise of an October Warrant, the holder will have the right to receive as alternative consideration, for each share of the Company’s common stock that would have been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction, the number of shares of common stock of the successor or acquiring corporation of the Company, if it is the surviving corporation, and any additional consideration receivable upon or as a result of such transaction by a holder of the number of shares of common stock for which the October Warrant is exercisable immediately prior to such event. Notwithstanding the foregoing, in the event of a fundamental transaction, the holders of the October Warrants have the right to require the Company or a successor entity to purchase the October Warrants for cash in the amount of the Black Scholes Value (as defined in the October Warrants) of the unexercised portion of the October Warrants concurrently with or within 30 days following the consummation of a fundamental transaction. However, in the event of a fundamental transaction which is not in the Company’s control or in which the consideration payable consists of equity securities of a successor entity that is quoted or listed on a nationally recognized securities exchange, the holders of the October Warrants will only be entitled to receive from the Company or its successor entity, as of the date of consummation of such fundamental transaction the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of the October Warrants that is being offered and paid to the holders of common stock in connection with the fundamental transaction, whether that consideration is in the form of cash, stock or any combination of cash and stock, or whether the holders of common stock are given the choice to receive alternative forms of consideration in connection with the fundamental transaction.
Amendment to May 2024 Series A Warrants
On October 30, 2024, the Company entered into amendments (the “Warrant Amendments”) with certain holders of an aggregate of
15
Table of Contents
APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES
FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2025
(unaudited)
NOTE E — CAPITAL STOCK, continued
Amendment to May 2024 Series A Warrants, continued
In connection with the October Registered Direct Offering, the Price Reset Mechanism in the May 2024 Series A Warrants was triggered, which resulted in the number of shares of common stock issuable upon exercise of the May 2024 Series A Warrants increasing from
As a result of the June 2025 Reverse Stock Split, the exercise Price Reset Mechanism was triggered for the May 2024 Series A Warrants, which resulted in the number of shares of common stock issuable upon exercise of the May 2024 Series A Warrants increasing from
May 2024 Series B Warrants Price and Share Adjustment
As a result of the March 2025 Reverse Stock Split, the exercise Price Reset Mechanism was triggered for the May 2024 Series B Warrants, which resulted in the number of shares of common stock issuable upon exercise of the May 2024 Series B Warrants increasing from
As a result of the June 2025 Reverse Stock Split, the exercise Price Reset Mechanism was triggered for the May 2024 Series B Warrants, which resulted in the number of shares of common stock issuable upon exercise of the May 2024 Series B Warrants, increasing from
The incremental change in fair value as a result of the modifications for the May 2024 Series A Warrants, the May 2024 Series B Warrants and the October 2024 Series D Warrants for the three and nine-month periods ended June 30, 2025 was $
Nasdaq Minimum Bid Price Requirement Deficiency Notifications
On November 12, 2024, the Company received written notice (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of thirty (30) consecutive business days (collectively, the “Bid Price Rule”). Based on the closing bid price of the Company’s common stock for the thirty-one (31) consecutive business days from September 27, 2024 to November 11, 2024, the Company no longer met the requirements of the Bid Price Rule. The Notification Letter did not impact the Company’s listing on The Nasdaq Capital Market at that time. The Notification Letter stated that the Company had 180 calendar days, or until May 12, 2025, to regain compliance with the Bid Price Rule.
On April 7, 2025, the Company received written notice (the “Compliance Notice”) from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires that companies listed on The Nasdaq Capital Market maintain a minimum bid price of $1.00 per share. Nasdaq notified the Company in the Compliance Notice that, from March 14, 2025 to April 4, 2025, the closing bid price of the Company’s common stock had been at $1.00 per share or greater and, accordingly, the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2) and that the matter was now closed.
16
Table of Contents
APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES
FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2025
(unaudited)
NOTE E — CAPITAL STOCK, continued
Nasdaq Minimum Bid Price Requirement Deficiency Notifications, continued
The Company received written notice dated May 30, 2025 (the “May 2025 Notification Letter”) from Nasdaq that the Company no longer satisfied the Bid Price Rule. Based on the closing bid price of the Company’s common stock, for the thirty-two (32) consecutive business days from April 14, 2025 to May 29, 2025, the Company did not comply with the Bid Price Rule.
The May 2025 Notification Letter further indicated that, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company was not eligible for a compliance period under Nasdaq Listing Rule 5810(c)(3)(A) due to the fact that the Company had effected a reverse stock split over the prior one-year period or had effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one; accordingly, the Company was informed that its securities were subject to delisting from Nasdaq unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company timely requested a hearing, which request will stay any further suspension or delisting action by Nasdaq at least pending the ultimate conclusion of the hearing process.
On July 2, 2025, the Company received written notice (the “July 2025 Compliance Notice”) from Nasdaq informing the Company that it had regained compliance with the Bid Price Rule, and that the Company is therefore in compliance with the Nasdaq Capital Market’s listing requirements. Nasdaq also notified the Company in the July 2025 Compliance Notice that the hearing before the Panel previously scheduled to take place on July 15, 2025 was cancelled and the Company’s securities will continue to be listed and traded on Nasdaq.
NOTE F —WARRANTS AND STOCK OPTIONS
Warrants
The following table summarizes the changes in warrants outstanding. These warrants were granted as part of financing transactions, as well as in lieu of cash compensation for services performed or as financing expenses in connection with the sales of the Company’s common stock. See Note E for details on the warrant activity during the nine-month period ended June 30, 2025.
| | | | | |
| | | | Weighted | |
| | | | Average | |
| | | | Exercise | |
| | Number of | | Price Per | |
|
| Shares |
| Share | |
Balance at October 1, 2024 | | | | $ | |
Granted | | | |
| |
Exercised | | ( | |
| |
Cancelled or expired | | ( | |
| |
Balance at June 30, 2025 | | | | $ | |
During the three and nine-month periods ended June 30, 2025,
During the three and nine - month periods ended June 30, 2025,
During the three and nine-month periods ended June 30, 2025, an aggregate of
17
Table of Contents
APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES
FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2025
(unaudited)
NOTE F —WARRANTS AND STOCK OPTIONS, continued
Stock Options
On May 22, 2025, at the Company’s annual shareholders’ meeting, an amendment to the Company’s 2020 Equity Incentive Plan to increase the number of authorized shares of common stock reserved for issuance by
NOTE G — COMMITMENTS AND CONTINGENCIES
Operating Leases
The Company leases office space under an operating lease in Stony Brook, New York for its corporate headquarters. The lease is for a
Employment Agreement
On June 16, 2025, Dr. James A. Hayward informed the Company of his intention to retire from the Company and that he would step down from his positions as Chief Executive Officer, member of the Company’s board of directors (the “Board”) and Chairman of the Board effective June 18, 2025. Dr. Hayward’s resignation was not the result of any dispute or disagreement with the Company or the Board on any matter relating to the Company’s operations, policies or practices.
In connection with Dr. Hayward’s retirement, Dr. Hayward and the Company entered into a separation agreement dated June 16, 2025 (the “Separation Agreement”), pursuant to which the Company shall pay to Dr. Hayward, contingent upon his compliance with the terms of the Separation Agreement, the total gross amount of $
On June 17, 2025, the Board elected Judith Murrah, the Company’s current President, as Chief Executive Officer and as Chairperson and a member of the Board effective June 18, 2025. Effective June 30, 2025, Ms. Murrah voluntarily agreed to a fifteen percent (
Litigation
From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. There is no pending litigation involving the Company at this time.
18
Table of Contents
APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES
FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2025
(unaudited)
NOTE H – SEGMENT INFORMATION
As detailed in Note B above, the Company currently has
Information regarding operations by segment for the three-month period ended June 30, 2025 is as follows:
| | | | | | | | | |
| | Therapeutic DNA | | DNA Tagging and | | | |||
|
| Production |
| Security Products |
| Consolidated | |||
Revenues: |
| |
|
| |
|
| |
|
Product revenues | | $ | | | $ | | | $ | |
Service revenues | |
| | | | | | | |
Less intersegment revenues | |
| — | |
| — | | | — |
Total revenues | | $ | | | $ | | | $ | |
| | | | | | | | | |
Gross profit | | $ | | | $ | ( | | $ | |
| | | | | | | | | |
Segment operating expenses | | | | | | | | | |
Selling, general and administrative | | $ | | | $ | | | $ | |
Research and development | | | | | | ( | | | |
Total segment operating expenses | | $ | | | $ | | | $ | |
Loss from segment operations (a) | | $ | ( | | $ | ( | | $ | ( |
Information regarding operations by segment for the three-month period ended June 30, 2024 is as follows:
| | | | | | | | | | | | |
| | Therapeutic DNA | | MDx Testing | | DNA Tagging and | |
| | |||
|
| Production |
| Services and Kits |
| Security Products |
| Consolidated | ||||
Revenues: |
| |
|
| |
|
| |
|
| |
|
Product revenues | | $ | | | $ | — | | $ | | | $ | |
Service revenues | |
| | | | — | | | | | | |
Clinical laboratory service revenues | |
| — | | | | | | — | | | |
Less intersegment revenues | |
| — | | | ( | | | — | | | ( |
Total revenues | | | | | | | | | | | | |
| | | | | | | | | | | | |
Gross profit | | | | | | ( | | | 63,151 | | | 245,232 |
| | | | | | | | | | | | |
Segment operating expenses | | | | | | | | | | | | |
Selling, general and administrative | | $ | | | $ | | | $ | | | $ | |
Research and development | | | | | | | | | | | | |
Total segment operating expenses | | $ | | | $ | | | $ | | | $ | |
Loss from segment operations (a) | | $ | ( | | $ | ( | | $ | ( | | $ | ( |
19
Table of Contents
APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES
FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2025
(unaudited)
NOTE H – SEGMENT INFORMATION, continued
Information regarding operations by segment for the nine-month period ended June 30, 2025 is as follows:
| | | | | | | | | |
| | Therapeutic DNA | | DNA Tagging and | |
|
| ||
|
| Production |
| Security Products |
| Consolidated | |||
Revenues: | |
|
| |
|
| |
|
|
Product revenues |
| $ | |
| $ | | | $ | |
Service revenues | | | | | | | | | |
Clinical laboratory service revenues | | | — | | | — | | | — |
Less intersegment revenues | | | — | | | — | | | — |
Total revenues |
| $ | |
| $ | | | $ | |
| | | | | | | | | |
Gross profit |
| $ | |
| $ | | | $ | |
| | | | | | | | | |
Segment operating expenses | | | | | | | | | |
Selling, general and administrative | | $ | | | $ | | | $ | |
Research and development | | | | | | | | | |
Total segment operating expenses | | $ | | | $ | | | $ | |
(Loss) income from segment operations (a) |
| $ | ( |
| $ | ( | | $ | ( |
Information regarding operations by segment for the nine-month period ended June 30, 2024 is as follows:
| | | | | | | | | | | | |
| | Therapeutic DNA | | MDx Testing | | DNA Tagging and | |
|
| |||
|
| Production |
| Services and Kits |
| Security Products |
| Consolidated | ||||
Revenues: | |
|
| |
|
| |
|
| |
|
|
Product revenues |
| $ | | | $ | — | | $ | | | $ | |
Service revenues | | | | | | — | | | | | | |
Clinical laboratory service revenues | | | — | | | | | | — | | | |
Less intersegment revenues | | | — | | | ( | | | — | | | ( |
Total revenues |
| $ | | | $ | | | $ | | | $ | |
| | | | | | | | | | | | |
Gross profit |
| $ | | | $ | ( | | $ | | | $ | 771,980 |
| | | | | | | | | | | | |
Segment operating expenses | | | | | | | | | | | | |
Selling, general and administrative | | $ | | | $ | | | $ | | | $ | |
Research and development | | | | | | | | | | | | |
Total segment operating expenses | | $ | | | $ | | | $ | | | $ | |
(Loss) income from segment operations (a) |
| $ | ( | | $ | ( | | $ | ( | | $ | ( |
20
Table of Contents
APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES
FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2025
(unaudited)
NOTE H – SEGMENT INFORMATION, continued
Reconciliation of loss from segment operations to Corporate (loss) income for the three-month periods ended June 30, 2025 and 2024 is as follows:
| | | | | | |
| | June 30, | ||||
|
| 2025 |
| 2024 | ||
Loss from operations of reportable segments | | $ | ( | | $ | ( |
General corporate expenses (b) | |
| ( | | | ( |
Interest income | |
| | | | |
Unrealized gain on change in fair value of warrants classified as a liability | |
| | | | |
Net loss from discontinued operations | | | ( | | | — |
Other (expense) income, net | |
| ( | | | ( |
Consolidated net (loss) income | | $ | ( | | $ | |
Reconciliation of loss from segment operations to Corporate loss for the nine-month periods ended June 30, 2025 and 2024 is as follows:
| | | | | | |
| | June 30, | ||||
|
| 2025 |
| 2024 | ||
Loss from operations of reportable segments |
| $ | ( |
| $ | ( |
General corporate expenses (b) | | | ( | | | ( |
Interest income | | | | | | |
Unrealized gain on change in fair value of warrants classified as a liability | | | | | | |
Unrealized loss on change in fair value of warrants classified as a liability - warrant modification |
| | — |
| | ( |
Transaction costs allocated to warrant liabilities | | | — | | | ( |
Loss on issuance of warrants | | | — | | | ( |
Other (expense) income, net |
| | ( |
| | ( |
Net loss from discontinued operations | | | ( | | | — |
Consolidated net loss | | $ | ( | | $ | ( |
(a) | Segment operating loss consists of net sales, less cost of sales, specifically identifiable research and development, and selling, general and administrative expenses. |
(b) | General corporate expenses consist of selling, general and administrative expenses that are not specifically identifiable to a segment. |
NOTE I – FAIR VALUE OF FINANCIAL INSTRUMENTS
The Company’s financial instruments at fair value are measured on a recurring basis. Related unrealized gains or losses are recognized in unrealized gain (loss) on change in fair value of the warrants classified as a liability in the condensed consolidated statements of operations. For additional disclosures regarding methods and assumptions used in estimating fair values of these financial instruments, see Note B.
The following tables present the fair value of the Company’s financial instruments as of June 30, 2025
| | | |
| | Fair value at | |
|
| June 30, 2025 | |
Liabilities: | | | |
Common Warrants | | $ | |
Series A Warrants | | $ | |
Series A Warrants - modified | | $ | |
Private Common Warrants | | $ | |
21
Table of Contents
APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES
FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2025
(unaudited)
NOTE I – FAIR VALUE OF FINANCIAL INSTRUMENTS, continued
The fair value of the warrants classified as a liability as of June 30, 2025, was determined using the Black Scholes and Probability Weighted Expected Return models. The fair value for the warrants classified as a liability as of June 30, 2025, was calculated using the following assumptions:
| | | | | | | | | | | | | |
|
| | |
| | |
| Series A |
| Private |
| ||
| | Common | | Series A | | Warrants – | | Common |
| ||||
| | Warrants | | Warrants | | modified | | Warrants |
| ||||
Stock price | | $ | | | $ | | | $ | | | $ | | |
Exercise price | | $ | | | $ | | | $ | | | $ | | |
Dividend yield | |
| | % |
| | % |
| | % |
| | % |
Selected Volatility | |
| | % |
| | % |
| | % |
| | % |
Risk free rate | |
| | % |
| | % |
| | % |
| | % |
Fundamental transaction probability | |
| | % |
| | % |
| | % |
| | % |
Fundamental transaction Black Scholes Volatility | |
| | % |
| | % |
| | % |
| | % |
Fundamental transaction timing | |
| 12/31/2025 | |
| 12/31/2025 | |
| 12/31/2025 | |
| 12/31/2025 | |
The Company did not have any assets or liabilities categorized as Level 1 or 2 as of June 30, 2025.
The change in fair value of the Common Warrants (issued in February 2024), the Series A Warrants (issued in February 2022) and the Private Common Warrants (issued in February 2024) for the three-month period ended June 30, 2025, is summarized as follows:
| | | | | | | | | | | | | | | |
| | | | | | Series A | | Private | | | |||||
| | Common | | Series A | | Warrants- | | Common | | | |||||
|
| Warrants |
| Warrants |
| modified |
| Warrants |
| Totals | |||||
Fair value at April 1, 2025 | | $ | | | $ | |
| | |
| | | | $ | |
Change in fair value | |
| ( | |
| ( |
| | ( |
| | ( | |
| ( |
Fair Value at June 30, 2025 | | $ | | | $ | | | $ | | | $ | | | $ | |
The change in fair value of the Common Warrants, the Series A Warrants and the Private Common Warrants for the nine-month period ended June 30, 2025 is summarized as follows:
| | | | | | | | | | | | | | | |
|
| | | | | Series A | | Private | | | |||||
| | Common | | Series A | | Warrants- | | Common | | | |||||
| | Warrants |
| Warrants |
| modified |
| Warrants |
| Totals | |||||
Fair value at October 1, 2024 | | $ | | | $ | |
| $ | |
| $ | | | $ | |
Change in fair value | | | ( | | | ( | |
| ( | |
| ( | | | ( |
Fair Value at June 30, 2025 | | $ | | | $ | | | $ | | | $ | | | $ | |
22
Table of Contents
APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES
FOOTNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2025
(unaudited)
NOTE J – DISCONTINUED OPERATIONS
On June 27, 2025, the Company implemented a strategic restructuring and realignment of resources to focus exclusively on its Therapeutic DNA Production Services business. As part of actions undertaken, the Company implemented a workforce reduction of approximately
The Company’s actions are intended to reduce its operating costs and concentrate resources on the development and commercialization of its Therapeutic DNA Production Services business. The Company expects to pay approximately three hundred thousand dollars ($
The following table presents the major classes of ADCL’s results within Net loss from discontinued operations, net of tax in the condensed consolidated statement of operations:
| | | | | | | | | | | | |
| | Three months Ended June 30, | | Nine months Ended June 30, | ||||||||
|
| 2025 |
| 2024 |
| 2025 |
| 2024 | ||||
Clinical laboratory service revenues | | $ | | | $ | | | $ | | | $ | |
| | | | | | | | | | | | |
Cost of clinical laboratory service revenues | |
| | |
| | |
| | | $ | |
| | | | | | | | | | | | |
Gross profit | |
| ( | |
| | |
| ( | |
| ( |
| | | | | | | | | | | | |
Selling, general and administrative | |
| | |
| | |
| | |
| |
Interest (Income) | |
| ( | |
| ( | |
| ( | |
| ( |
Other (income), net | |
| ( | |
| — | |
| ( | |
| — |
Net loss from discontinued operations | |
| ( | |
| ( | |
| ( | |
| ( |
Provision for income taxes | |
| — | |
| — | |
| — | |
| — |
Net loss from discontinued operations, net of tax | | $ | ( | | $ | ( | | $ | ( | | $ | ( |
Assets and liabilities of discontinued operations associated with ADCL presented in the condensed consolidated balance sheet as of June 30, 2025 and September 30, 2024 are included in the following table:
| | | | | | |
|
| June 30, |
| September 30, | ||
| | 2025 | | 2024 | ||
ASSETS | | | | | | |
Cash and cash equivalents | | $ | | | $ | |
Accounts receivable, net | |
| | |
| |
Inventories | |
| — | |
| |
Prepaid expenses and other current assets | |
| — | |
| |
Total current assets of discontinued operations | |
| | |
| |
Property and equipment, net | |
| | |
| |
Total assets of discontinued operations | |
| | |
| |
| | | | | | |
LIABILITIES | |
|
| |
|
|
Accounts payable and accrued liabilities | |
| | |
| |
Total liabilities of discontinued operations | | $ | | | $ | |
23
Table of Contents
Item 2. — Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Forward-Looking Statements
This Quarterly Report on Form 10-Q (including but not limited to this Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are intended to qualify for the “safe harbor” created by those sections. In addition, we may make forward-looking statements in other documents filed with or furnished to the SEC, and our management and other representatives may make forward-looking statements orally or in writing to analysts, investors, representatives of the media and others. These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements.
Forward-looking statements can generally be identified by the fact that they do not relate strictly to historical or current facts and include, but are not limited to, statements using terminology such as “can”, “may”, “could”, “should”, “assume”, “forecasts”, “believe”, “designed to”, “will”, “expect”, “plan”, “anticipate”, “estimate”, “potential”, “position”, “predicts”, “strategy”, “guidance”, “intend”, “budget”, “seek”, “project” or “continue”, or the negative thereof or other comparable terminology regarding beliefs, plans, expectations or intentions regarding the future. You should read statements that contain these words carefully because they:
| ● | discuss our future expectations; |
| ● | contain projections of our future results of operations or of our financial condition; and |
| ● | state other “forward-looking” information. |
We believe it is important to communicate our expectations. However, forward-looking statements are based on our current expectations, assumptions, estimates and projections about our business and our industry and are subject to known and unknown risks, uncertainties and other factors. Accordingly, our actual results and the timing of certain events may differ materially from those expressed or implied in such forward-looking statements due to a variety of factors and risks, including, but not limited to, those set forth in this Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in our unaudited condensed consolidated financial statements and notes thereto included in this Quarterly Report, those set forth from time to time in our other filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2024, and the following factors and risks:
| ● | our expectations of future revenues, expenditures, capital or other funding requirements; |
| ● | the adequacy of our cash and working capital to fund present and planned operations and growth; |
| ● | the substantial doubt relating to our ability to continue as a going concern; |
| ● | our need for additional financing which may in turn require the issuance of additional shares of common stock, preferred stock or other debt or equity securities (including convertible securities) which would dilute the ownership held by stockholders; |
| ● | our identification of a material weakness in our internal control over financial reporting; |
| ● | our business strategy, including our concentration on Therapeutic DNA Production Services, which is unproven and for which demand may not materialize; |
| ● | the timing of our expansion plans, including the development of new production facilities for our nucleic-acid production solutions; |
| ● | demand for Therapeutic DNA Production Services; |
| ● | our expectations concerning existing or potential development and license agreements for third-party collaborations or joint ventures; |
24
Table of Contents
| ● | regulatory approval and compliance for our Therapeutic DNA Production Services, upon which our business strategy is substantially dependent; |
| ● | the effect of governmental regulations generally; |
| ● | our expectations of when regulatory submissions may be filed or when regulatory approvals may be received; |
| ● | our expectations concerning restructuring of our business model with an emphasis on Therapeutic DNA Production Services; |
| ● | our expectations of when or if we will become profitable; |
| ● | the risk that our stockholders may suffer substantial dilution if certain provisions of our outstanding warrants are utilized; |
| ● | the 2025 Reverse Stock Splits may decrease the liquidity of the shares of our common stock and the resulting market price of our common stock may not attract or satisfy the investing requirements of new investors, including institutional investors; |
| ● | the risk that our common stock may be delisted from Nasdaq if we fail to comply with the Bid Price Rule or with any other listing requirements of The Nasdaq Capital Market; |
| ● | the risk that any stock splits we may implement in the future may decrease our liquidity and the price of our common stock; |
| ● | the potential impact of amended Nasdaq Listing Rules 5810 and 5815, which may in certain circumstances prevent the Company from utilizing reverse stock splits to regain compliance with Nasdaq Listing Rules; |
| ● | any impacts from current global, economic, sovereign and political conditions and uncertainties, including the effects of, and uncertainty regarding new or proposed tariff or trade regulations. |
Any or all of our forward-looking statements may turn out to be wrong. They may be affected by inaccurate assumptions that we might make or by known or unknown risks and uncertainties. Actual outcomes and results may differ materially from what is expressed or implied in our forward-looking statements. Among the factors that could affect future results are:
| ● | the inherent uncertainties of product development based on our new and as yet not fully proven technologies; |
| ● | the risks and uncertainties regarding the actual effect on humans of seemingly safe and efficacious formulations and treatments when tested clinically; |
| ● | the inherent uncertainties of formulations and treatments that utilize our Therapeutic DNA Production Services; |
| ● | the inherent uncertainties associated with clinical trials of product candidates, including product candidates that utilize our Therapeutic DNA Production Services; |
| ● | the inherent uncertainties associated with the process of obtaining regulatory clearance or approval to market product candidates, including product candidates that utilize our Therapeutic DNA Production Services; |
| ● | the inherent uncertainties associated with commercialization of products that have received regulatory clearance or approval, including products that utilize our Therapeutic DNA Production Services; |
| ● | economic and industry conditions generally and in our specific markets; |
| ● | the volatility of, and decline in, our stock price; and |
| ● | our ability to obtain the necessary financing to fund our operations and effect our strategic development plan. |
25
Table of Contents
Forward-looking statements may include our plans and objectives for future operations, including plans and objectives relating to our products and our future economic performance, projections, business strategy and timing and likelihood of success. Assumptions relating to the forward-looking statements included in this Quarterly Report involve judgments with respect to, among other things, future economic, competitive and market conditions, future business decisions, regulatory outcomes, safety and efficacy, demand for our products and services, and the time and money required to successfully complete development and commercialization of our technologies, all of which are difficult or impossible to predict accurately and many of which are beyond our control.
Any of the assumptions underlying the forward-looking statements contained in this Quarterly Report could prove inaccurate and, therefore, we cannot assure you that any of the results or events contemplated in any of such forward-looking statements will be realized. Based on the significant uncertainties inherent in these forward-looking statements, the inclusion of any such statement should not be regarded as a representation or as a guarantee by us that our objectives or plans will be achieved, and we caution you against relying on any of the forward looking statements contained herein.
Our trademarks currently used in the United States include Applied DNA Sciences®, LineaDNATM, LineaRNAPTM, LineaIVTTM and LineaRxTM. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. All trademarks, service marks and trade names included in this Quarterly Report on Form 10-Q are the property of the respective owners.
Introduction
Applied DNA Sciences is a biotechnology company focused on providing nucleic-acid production solutions for the biopharmaceutical and diagnostics industries. Our technologies enable the rapid and efficient cell-free manufacturing of high-quality DNA and RNA, which are essential components for a new generation of advanced biotherapeutics such as gene therapies, personalized medicine, adoptive cell therapies, and mRNA and DNA-based vaccines, as well as in vitro diagnostic (“IVD”) applications.
The Company has developed three distinct and complementary technology solutions:
| ● | LineaDNA™: A proprietary, cell-free DNA production system that uses a large-scale polymerase chain reaction (PCR) process. This technology allows for the rapid and efficient production of high-fidelity synthetic DNA without the use of living cells. The resulting DNA can be used in the manufacturing of various biotherapeutics, serve as the starting material for mRNA therapeutics and vaccines, and as a critical component of IVDs. |
| ● | LineaRNAP™: A next-generation RNA polymerase (“RNAP”) used to transform DNA into mRNA. Our RNAP is engineered with a patented DNA-binding domain that we believe results in high mRNA yields and reduced double-stranded RNA (dsDNA) contamination, a common problematic byproduct produced during mRNA production. |
| ● | LineaIVT™: An integrated system that combines the Company’s LineaDNA and LineaRNAP technologies. This innovative solution simplifies the mRNA production workflow resulting in a streamlined production process with fewer impurities than traditional methods. |
We believe our technology solutions address significant unmet needs, allowing us and our customers to produce DNA and RNA biotherapeutics and diagnostic solutions with unmatched quality and speed. Our business strategy is to focus our resources on further development, commercialization, and customer adoption of our three commercial technology solutions within product and therapeutic modalities where our unique business solutions have distinct advantages over legacy technologies.
Specifically, for the biotherapeutic markets we seek to: (i) capitalize on the rapid growth of DNA needed for advanced biotherapeutics generally via LineaDNA to supply synthetic DNA to customers for use in biotherapeutic discovery and manufacturing; and (ii) leverage LineaDNA, LineaRNAP and LineaIVT to specifically capitalize on the near term growing demand for materials used in mRNA-based drug discovery and manufacturing. For the IVD market, we seek to gain additional market adoption for LineaDNA as a component used in the discovery and manufacturing of various diagnostic technologies with a focus on applications requiring chemically modified DNA.
26
Table of Contents
LineaDNA
LineaDNA is our core enabling technology for rapid, efficient, and scalable cell-free manufacture of high-fidelity synthetic DNA sequences used in the manufacturing of a broad range of biotherapeutics. The LineaDNA platform enzymatically produces a linear form of synthetic DNA we call “LineaDNA” that is an alternative to plasmid-based DNA manufacturing technologies that have supplied the DNA used in biotherapeutics for the past 40 years. LineaDNA can be quickly produced in batches ranging from milligram to grams under a variety of controlled manufacturing processes including research use only (RUO), good laboratory practices (GLP) and good manufacturing practices (GMP).
As of the first quarter of calendar year 2025, there were 4,418 gene, cell and RNA therapies in development from preclinical through pre-registration stages, almost all of which use DNA in their manufacturing process. (Source: ASGCT Gene, Cell & RNA Therapy Landscape: Q1 2025 Quarterly Report). Due to what we believe are the LineaDNA’s numerous advantages over legacy nucleic DNA manufacturing platforms, we believe this large number of therapies under development represents a substantial market opportunity for LineaDNA to supplant legacy DNA manufacturing as the source of DNA used during manufacturing.
We believe LineaDNA holds several important advantages over existing cell-based plasmid DNA manufacturing platforms. Plasmid-based DNA manufacturing is based on the complex, costly and time-consuming biological process of amplifying DNA in living bacterial cells. Once amplified, the DNA must be separated from the living cells and other process contaminants via multiple rounds of purification, adding further complexity and costs. Unlike plasmid-based DNA manufacturing, LineaDNA does not require living cells and instead amplifies DNA via the exponential enzymatic process of PCR. The LineaDNA platform is simple, scalable and can rapidly produce large quantities of DNA with minimal purification steps.
We believe the key advantages of LineaDNA include:
| ● | Speed – Production of LineaDNA can be measured in terms of hours, not days and weeks as is the case with plasmid-based DNA manufacturing platforms. |
| ● | Scalability – LineaDNA production takes place on efficient bench-top instruments with proprietary processes, allowing for rapid scalability in a minimal footprint resulting in reduced capital expenditure requirements. |
| ● | Purity – LineaDNA produced via PCR is pure, resulting in large quantities of only the target DNA sequence. Unwanted DNA sequences such as the plasmid backbone and antibiotic resistance genes, inherent to plasmid DNA, are not present in LineaDNA. In addition, we believe utilizing PCR removes common safety risks associated with plasmid DNA such as endotoxin and host cell genomic and protein contamination. |
| ● | Simplicity – The production of LineaDNA is streamlined relative to plasmid-based DNA production. LineaDNA requires only four primary ingredients, does not require living cells or complex fermentation systems and does not require multiple rounds of purification. |
| ● | Flexibility – LineaDNA can be easily chemically modified to suit specific customer applications and provides for different physical forms of DNA such as the production of single stranded DNA (ssDNA) and circular double-stranded DNA (cirDNA). In addition, LineaDNA can produce a wide range of complex DNA sequences that are difficult to produce via plasmid-based DNA production platforms. These complex sequences include, without limitation, inverted terminal repeats and long homopolymers such as polyadenylation sequences (poly (A) tail) important for gene therapy and mRNA therapies, respectively. |
Preclinical studies conducted by the Company have shown that LineaDNA is substitutable for plasmid DNA in numerous biotherapeutic applications, including:
| ● | DNA vaccines; |
| ● | DNA templates to produce RNA, including mRNA therapeutics; |
| ● | adoptive cell therapy (CAR-T) manufacturing; and |
| ● | homology-directed repair (HDR)-mediated gene editing. |
27
Table of Contents
Further, we believe that LineaDNA is also substitutable for plasmid DNA in the following nucleic acid-based therapies:
| ● | viral vector manufacturing for in vivo and ex vivo gene editing; |
| ● | clustered regularly interspaced short palindromic repeats-mediated gene therapy (CRISPR); and |
| ● | non-viral gene therapy. |
LineaRNAP
The number of mRNA therapies under development is growing at a rapid rate, triggered in part by the success of the mRNA COVID-19 vaccines and the recent clinical success of personalized cancer therapeutics. As of the third quarter of calendar 2024, there were over 450 mRNA therapies under development, with the majority of these therapies (65%) in the preclinical stage (Source: ASGCT Gene, Cell & RNA Therapy Landscape: Q1 2025 Quarterly Report). The Company believes that the mRNA market is in a nascent stage that represents a large growth opportunity for the Company via the production and supply of our next-generation LineaRNAP to produce mRNA therapies from DNA templates.
mRNA therapeutics are produced via a process called in vitro transcription (“IVT”) that requires a DNA template and RNAP as starting materials. Typically, the RNAP is derived from the T7 bacteriophage (“WT-T7”). LineaRNAP is a patented next generation WT-T7-based RNAP engineered with a proprietary DNA-binding domain resulting we believe in high mRNA yields, increased mRNA integrity and reduced double-stranded RNA (dsDNA) contamination as compared to conventional WT-T7. LineaRNAP is engineered for use either as a direct replacement for WT-T7 in conventional IVT workflows or with chemically modified LineaDNA templates and a proprietary reaction buffer, the latter marketed as our LineaIVT platform.
Company data shows that when used in conventional IVT systems (either using synthetic DNA or plasmid DNA templates), LineaRNAP results in higher mRNA yields, lower dsRNA contamination and higher mRNA integrity when compared to WT-T7. The Company seeks to commercialize LineaRNAP as a standalone product sold to third parties for use in mRNA production workflows that use either synthetic or plasmid DNA templates.
LineaRNAP is produced for the Company under an ISO 13485 quality system by Alphazyme, LLC (“Alphazyme”), a third-party Contract Development and Manufacturing Organization (“CDMO”) located in the United States, which the Company believes is sufficient for early-stage clinical use of the enzyme. In conjunction with Alphazyme, the Company completed manufacturing process development work on its LineaRNAP to increase the production scale of the enzyme and reduce unit costs. The Company believes current manufacturing capacity for LineaRNAP provided by Alphazyme is sufficient to meet near term needs.
LineaIVT
LineaIVT is an innovative integrated system for mRNA manufacturing input materials that combines: (i) the Company’s chemically modified LineaDNA IVT templates; (ii) LineaRNAP; and (iii) a proprietary IVT reaction buffer to simplify mRNA workflows and reduce dsRNA.
The LineaIVT platform leverages our patented LineaRNAP’s DNA binding domain to chemically bind to chemically modified LineaDNA IVT templates, enabling the use of a proprietary IVT reaction buffer. Internal data shows that the LineaIVT system can reduce dsRNA contamination between 10x and 50x as compared to conventional system for the manufacture of mRNA while achieving equivalent or greater target mRNA yields.
We believe the key advantages of the LineaIVT platform include:
| ● | The reduction of dsRNA contamination resulting in higher target mRNA yields with the potential to reduce downstream processing steps. dsRNA is a problematic immunogenic byproduct produced during conventional mRNA manufacture; |
| ● | delivery of LineaDNA IVT templates in as little as 14 days for milligram scale and 30 days for gram scale; |
| ● | reduced manufacturing complexities through single sourcing and potentially reduced mRNA purification requirement to meet target quality standards; and |
28
Table of Contents
| ● | potentially enabling mRNA manufacturers to produce mRNA drug substance in less than 45 days. |
Manufacturing Scale-up
The Company offers or plans to offer several quality grades of LineaDNA, each of which will have different permitted uses.
LineaDNA Quality Grade | Permitted Use | Company Status |
RUO | Research and pre-clinical discovery | Currently available |
GMP for Starting Materials | DNA critical starting materials for the production of mRNA therapies | Currently available |
GMP for Drug Substance | DNA biologic, drug substance and/or drug product | Planned availability in 2H CY 2026 |
We currently manufacture LineaDNA pursuant to GLP and in January 2025 completed the buildout of a fit for purpose manufacturing facility within our current Stony Brook, NY facility capable of producing LineaDNA IVT templates under GMP suitable for use as a critical starting material for clinical and commercial mRNA therapeutics and vaccines.
As of February 2026, the FDA has announced harmonization of GMP requirements with ISO 13485 quality standards. We are currently pursuing ISO 13485 certification, which is expected to be completed in FY2026 Q1.
Our current GMP manufacturing site can produce up to 10 grams of LineaDNA DNA annually, running at single shift capacity. In addition, the Company has additional annual manufacturing capacity for RUO LineaDNA of more than 15 grams per year. We believe our current manufacturing capabilities are sufficient to support near-term customer demand.
In addition, we believe our GMP manufacturing site can support LineaDNA manufactured under GMP suitable for use as, or incorporation into, a biologic, drug substance and/or drug product, which we currently expect to be available during the second half of calendar year 2026. Drug substances are the pharmaceutically active components of drug products.
The Company also plans to offer several quality grades of LineaRNAP, each of which will have different permitted uses. Currently, all manufacturing of LineaRNAP is performed by a CDMO (Alphazyme, LLC):
LineaRNAP Quality Grade | Permitted Use | Company Status |
RUO | Research and pre-clinical discovery | Currently available |
GMP Suitable for Early Clinical Trials | Use to make mRNA used for IND-enabling studies and early-stage clinical trials | Currently available under ISO 13485 QMS |
GMP | Use to manufacture mRNA used in late-stage clinical trials and commercial manufacturing | Planned availability in 2H CY2026 |
The Company plans to work with its current enzyme manufacturer CDMO (Alphazyme, LLC) or other third-party manufacturers to continue to reduce manufacturing unit costs. In addition, and based on customer demand, the Company plans to explore full GMP manufacturing of LineaRNAP with its current or other third-party CDMOs during FY2026, with planned availability in 2H CY2026.
Segment Business Strategy
We believe our technology solutions are differentiated in the market and offer compelling commercial advantages over legacy technologies. We seek to leverage our technology solutions to gain market share for our nucleic acid (both DNA and mRNA) production solutions.
Our business strategy relating to the biotherapeutics market is twofold: (i) to capitalize on the rapid growth of biotherapeutics requiring DNA generally via our LineaDNA platform to supply synthetic DNA to customers for use in biotherapeutic discovery and manufacturing; and (ii) to leverage LineaDNA, LineaRNAP and LineaIVT to specifically capitalize on the near term growing demand for input materials used in mRNA-based drug discovery and manufacturing.
29
Table of Contents
In addition, we seek to capitalize on the growing demand within the IVD sector for chemically modified and/or linear synthetic DNA as a component used in the development manufacture of diagnostic technologies. We believe demand for this market is evidenced by the Company’s existing multi-year, multi-order contract with a global IVD manufacturer.
Currently we offer fee-for-service manufacturing under our technology solutions. In the future, we may consider exploring technology out-licensing models for some or all of our technology solutions. In addition, we seek to strike collaborations both upstream and downstream of our technology solutions within the biotherapeutic manufacturing marketplace. Examples of downstream collaborations may include, without limitation, de novo synthesis of long DNA sequences or shorter DNA oligonucleotides. Examples of upstream collaborations may include CDMOs manufacturing biotherapeutic products and/or drug substances, including without limitation mRNA.
Comparison of Results of Operations for the Three -Month Periods Ended June 30, 2025 and 2024
Revenues
Product revenues
For the three-month periods ended June 30, 2025 and 2024, we generated $195,262 and $246,644 in revenues from product sales, respectively. Product revenues decreased by $51,382 or 21% for the three-month period ended June 30, 2025 as compared to the three-month period ended June 30, 2024. The decrease in product revenues was primarily related to a decrease of approximately $58,000 due to the timing of orders from our large-scale DNA manufacturing business within our Therapeutic DNA Production Services segment.
Service Revenues
For the three-month periods ended June 30, 2025 and 2024, we generated $109,131 and $226,145 in revenues from sales of services, respectively. The decrease in service revenues of $117,014 or 52% for the three-month period ended June 30, 2025, as compared to the same period in the prior fiscal year is attributable to a decrease within our DNA Tagging and Security Products and Services segment related to a decline in our textile isotopic testing services, due to the wind down of our tagging business.
Cost and Expenses
Gross Profit
Gross profit for the three-month period ended June 30, 2025, decreased by $237,471 or 98% from $242,601 for the three-month period ended June 30, 2024 to $5,130. The gross profit percentage was 2% and 51% for the three-month periods ended June 30, 2025 and 2024, respectively. The decline in gross profit percentage was primarily the result of lower product and service revenue during the current period, as compared to the same period in the prior fiscal year. The higher volume of both product and service revenues in the prior period was able to better absorb the fixed costs that are included in cost of product revenues.
Selling, General and Administrative
Selling, general and administrative expenses for the three-month period ended June 30, 2025 increased by $294,764 or 11% to $2,930,627 as compared to $2,635,863 for the three-month period ended June 30, 2024. The increase is primarily attributable to an increase in salaries and wages for the accrual of $450,000 related to the separation agreement with the former CEO. This increase was offset by decreases in professional fees of approximately $47,000, primarily for a reduction in accounting fees, as well as a decrease in investor relation and D&O insurance expenses of approximately $42,000 and 23,000, respectively. Consulting expense also declined by approximately $30,000.
Research and Development
Research and development expenses decreased to $768,563 for the three-month period ended June 30, 2025 from $913,031 for the three-month period ended June 30, 2024, a decrease of $144,468 or 16%. This decrease was attributable to decreased payroll charges of approximately $134,000, as well as a decrease in laboratory supplies of $135,000 for the development of an enzyme during the prior year period. These decreases were offset by an increase in consulting expense of $82,000 related to a development project during the three-month period ended June 30, 2025.
30
Table of Contents
Interest income
Interest income for the three-month period ended June 30, 2025 increased $10,549 or 36% to $40,237 as compared to $29,688 in the three-month period ended June 30, 2024 due to interest earned on our money market accounts.
Unrealized gain on change in fair value of warrants classified as a liability
Unrealized gain on change in fair value of warrants classified as a liability for the three-month periods ended June 30, 2025 and 2024 was $6,410 and $5,160,000, respectively, which relates to the change in fair value of the warrants that are classified as a liability. The primary driver of the change is the decrease in our stock price.
Other expense, net
Other expense, net for the three-month periods ended June 30, 2025 and 2024, was $531 and $103, respectively.
Loss from operations
Loss from operations increased $387,767, or 12% to $3,694,060 for the three-month period ended June 30, 2025 compared to $3,306,293 for the three-month period ended June 30, 2024 due to the factors noted above.
Comparison of Results of Operations for the Nine-Month Periods Ended June 30, 2025 and 2024
Revenues
Product revenues
For the nine-month periods ended June 30, 2025 and 2024, we generated $1,239,747 and $947,086 in revenues from product sales, respectively. Product revenue increased by $292,661 or 31% for the nine-month period ended June 30, 2025 as compared to the same period in the prior fiscal year. The increase in product revenues was primarily within our Therapeutic DNA Production Services segment for an increase in shipments for our large-scale DNA manufacturing business of approximately $191,000, as well as a net increase of approximately $100,000 within our DNA Tagging and Security Products and Services segment primarily attributable to an increase of approximately $230,000 year over year in cotton DNA tagging revenue, offset by a decrease of approximately $87,000 in sales to a nutraceutical customer.
Service revenues
For the nine-month periods ended June 30, 2025 and 2024 we generated $697,759 and $678,777 in revenues from sales of services, respectively. The increase in service revenues of $18,982 or 3% for the nine-month period ended June 30, 2025, as compared to the same period in the prior fiscal year is attributable to increases of approximately $83,000 for isotopic testing services for textiles within our DNA Tagging and Security Products and Services segment, offset primarily by a decrease of approximately $43,000 related to research and development projects within our Therapeutic DNA Production Services segment.
Cost and Expenses
Gross Profit
Gross profit for the nine-month period ended June 30, 2025, increased by $234,058 or 30% from $772,829 for the nine-month period ended June 30, 2024 to $1,006,887. The gross profit percentage was 52% and 48% for the nine-month periods ended June 30, 2025 and 2024, respectively. The increase in gross profit percentage was primarily the result of higher product revenues during the nine-month period ended June 30, 2025 as compared to the same period in the prior fiscal year. The higher volume of product revenues in the current period was able to better absorb the fixed costs that are included in cost of product revenues. To a lesser extent, the improved gross profit percentage was due to product mix, as during the nine-months ended June 30, 2025, the majority of our product revenue was for the shipment of DNA for cotton tagging within our DNA Tagging and Security Products and Services segment, which is at a higher gross margin compared to the product sales during the same period in the prior fiscal year.
31
Table of Contents
Selling, General and Administrative
Selling, general and administrative expenses remained consistent at $8,423,602 and $8,440,919 for the nine-month periods ended June, 2025 and 2024, respectively.
Research and Development
Research and development expenses decreased to $2,632,931 for the nine-month period ended June 30, 2025 from $2,762,040 for the nine-month period ended June 30, 2024, a decrease of $129,109 or 5%. This decrease was attributable to decreased payroll charges of $236,000 offset by an increase in laboratory supplies of approximately $298,000 for the development of an enzyme within our Therapeutic DNA Production Services segment.
Interest income
Interest income for the nine-month period ended June 30, 2025 increased $134,773 or 397% to $168,762 as compared to $33,989 in the nine-month period ended June 30, 2024 due to interest earned on our money market accounts, which had higher cash balances during the current period, coupled with higher interest rates.
Transaction costs allocated to warrant liabilities
Transaction cost allocated to warrant liabilities for the nine-month period ended June 30, 2024 was $633,198. These transaction costs represent the closing costs from the February 2024 financing transaction. These costs were expensed as it would have resulted in negative additional paid in capital.
Unrealized gain on change in fair value of warrants classified as a liability
Unrealized gain on change in fair value of the warrants classified as a liability for the nine-month periods ended June 30, 2025 and 2024 was $318,840 and $9,564,000, respectively, and relates to the change in fair value of the warrants that are classified as a liability. The primary driver of the change is the decrease in our stock price.
Unrealized loss on change in fair value of warrants classified as a liability-warrant modification
Unrealized loss on change in fair value of warrants classified as a liability-warrant modification of $394,000 for the nine-month period ended June 30, 2024 represents the change in fair value for the modifications made to certain warrants as a result of the February 2024 financing transaction.
Loss on issuance of warrants
The loss on issuance of warrants of $1,633,767 for the nine-month period ended June 30, 2024 relates to the February 2024 financing transaction and is the result of the fair value of the warrants being greater than the cash received from the financing.
Other expense, net
Other expense, net for the nine-month periods ended June 30, 2025 and 2024, was $23,778 and $9,060, respectively.
Loss from operations
Loss from operations decreased $380,484, or 4% from $10,430,130 for the nine-month period ended June 30, 2024 compared to $10,049,646 for the nine-month period ended June 30, 2025 due to the factors noted above.
Liquidity and Capital Resources
Our liquidity needs consist of our working capital requirements and research and development expenditure funding. As of June 30, 2025, we had working capital of $3,692,499, which excludes current assets and current liabilities of discontinued operations. For the nine-month period ended June 30, 2025, we used cash in operating activities of $9,141,688 consisting primarily of our loss of $9,585,822 net with non-cash adjustments of $255,601 in depreciation and amortization charges, $318,840 in unrealized gain on change in fair value
32
Table of Contents
of warrants classified as a liability, $5,212 in write-off of property and equipment, and $80,373 in stock-based compensation expense. Additionally, we had a net increase in operating assets of $545,522 and a net decrease in operating liabilities of $129,157. At June 30, 2025, we had cash and cash equivalents of $4,727,677.
We have recurring net losses. We incurred a net loss from continuing operations of $9,585,822 and generated negative operating cash flow of $9,141,688 for the nine-month period ended June 30, 2025. These factors raise substantial doubt about our ability to continue as a going concern for one year from the issuance of these financial statements. The ability of the Company to continue as a going concern is dependent on our ability to further implement our business plan, raise capital, and generate revenues. The financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.
Our current capital resources include cash and cash equivalents, accounts receivable and inventories. Historically, we have financed our operations principally from the sale of equity and equity-linked securities.
As discussed in Note E to our condensed consolidated financial statements, on October 31, 2024, we closed on a registered direct offering and received net proceeds, after deducting placement agent fees and other offering expenses payable by us, of approximately $5.7 million. We also received proceeds from the exercise of warrants of $2,220,459 during the nine months ended June 30, 2025 and $292,305 in proceeds from warrant exercises subsequent to June 30, 2025.
As detailed in Note A in our condensed consolidated financial statements, as a result of the strategic restructurings that occurred during January and June 2025, the Company completed a workforce reduction that reduced headcount by a total of 39% for a projected 31% total reduction in payroll expenses as compared to the fiscal year ended September 30, 2024. The projected annual payroll savings is expected to be partially offset by approximately three hundred thousand dollars ($300,000) in one-time charges related to the June 30, 2025 workforce reduction.
Critical Accounting Estimates and Policies
Financial Reporting Release No. 60, published by the SEC, recommends that all companies include a discussion of critical accounting policies used in the preparation of their financial statements. While all these significant accounting policies impact our financial condition and results of operations, we view certain of these policies as critical. Policies determined to be critical are those policies that have the most significant impact on our consolidated financial statements and require management to use a greater degree of judgment and estimates. Actual results may differ from those estimates.
We believe that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies would cause a material effect on our condensed consolidated results of operations, financial position or liquidity for the periods presented in this report.
The accounting policies identified as critical are as follows:
| ● | Revenue recognition; and |
| ● | Warrant Liabilities. |
Critical Accounting Estimates
The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The most critical estimates include recoverability of long-lived assets, including the values assigned to intangible assets, fair value calculations for warrants, and contingencies. Management reviews its estimates on a regular basis and the effects of any material revisions are reflected in the consolidated financial statements in the period they are deemed necessary. Accordingly, actual results could differ from those estimates.
Revenue Recognition
We follow FASB issued accounting standard updates which clarify the principles for recognizing revenue arising from contracts with customers (“ASC 606” or “Topic 606”).
33
Table of Contents
The Company measures revenue at the amounts that reflect the consideration to which it is expected to be entitled in exchange for transferring control of goods and services to customers. The Company recognizes revenue either at the point in time or over the period of time that performance obligations to customers are satisfied. The Company’s contracts with customers may include multiple performance obligations (e.g. DNA products, maintenance, authentication services, research and development services, etc.). For such arrangements, the Company allocates revenues to each performance obligation based on their relative standalone selling price.
Due to the short-term nature of the Company’s current contracts with customers, it has elected to apply the practical expedients under Topic 606 to: (1) expense as incurred, incremental costs of obtaining a contract and (2) not adjust the consideration for the effects of a significant financing component for contracts with an original expected duration of one year or less.
Product Revenues
The Company’s DNA product revenues are accounted for/recognized in accordance with contracts with customers. The Company recognizes revenue upon satisfying its promises to transfer goods or services to customers under the terms of its contracts. These performance obligations are satisfied at the point in time the Company transfers control of the goods to the customer, which in nearly all cases is when title to and risk of loss of the goods transfer to the customer. The timing of transfer of title and risk of loss is dictated by customary or explicitly stated contract terms. The Company invoices customers upon shipment, and its collection terms range, on average, from 30 to 60 days.
Authentication Services
The Company recognizes revenue from authentication services upon satisfying its promises to provide services to customers under the terms of its contracts. These performance obligations are satisfied at the point in time the Company services are complete, which in nearly all cases is when the authentication report is released to the customer.
Research and Development Services
The Company’s revenue from its research and development contracts are accounted for/recognized when the performance obligations per the contract are satisfied. These performance obligations are satisfied at the point in time, either when the Company’s services are complete, or when the Company transfers control of the goods to the customer, which in nearly all cases is when title to and risk of loss of the goods transfer to the customer, or when a report is released to a customer. The timing of transfer of title and risk of loss is dictated by customary or explicitly stated contract terms. The Company invoices customers upon shipment, or completion of the services and its collection terms range, on average, from 30 to 60 days.
Warrant Liabilities
The Company evaluates its issued warrants in accordance with ASC 480 “Distinguishing Liabilities from Equity” and ASC 815-40, “Derivatives and Hedging — Contracts in Entity’s Own Equity” and concluded that due to the terms of certain of its warrant agreements, the instruments do not qualify for equity treatment. As such, the Common Warrants, Series A Warrants and Private Common Warrants were recorded as a liability on the consolidated balance sheet and measured at fair value at inception and at each reporting date in accordance with ASC 820, “Fair Value Measurement”, with changes in fair value recognized in the condensed consolidated statement of operations in the period of change.
Off-Balance Sheet Arrangements
As a requirement of our lease agreement for our corporate headquarters entered into during January 2023, in lieu of security deposit, we provided a standby letter of credit of $750,000. The letter of credit is effective through January 2026.
Inflation
The effect of inflation on our revenue and operating results was not significant.
Item 3. — Quantitative and Qualitative Disclosures About Market Risk.
Information requested by this Item is not applicable as we are electing scaled disclosure requirements available to smaller reporting companies with respect to this Item.
34
Table of Contents
Item 4. — Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
As of the end of the period covered by this Quarterly Report on Form 10-Q, we conducted an evaluation, under the supervision of and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Disclosure controls and procedures are those controls and procedures designed to provide reasonable assurance that the information required to be disclosed in our Exchange Act filings is (1) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (2) accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2025, our disclosure controls and procedures were not effective because of a material weakness in our internal control over financial reporting as of June 30, 2025. The material weakness is further described below.
Material Weakness in Internal Control Over Financial Reporting
In connection with the review of our condensed consolidated financial statements for the nine-month period ended March 31, 2025, we identified a material weakness in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. For the nine-month period ended June 30, 2025, the material weakness related to the controls around the preparation and review of the inputs utilized in fair value calculations, specifically as it related to warrant modifications. Nonetheless, we have concluded that this material weakness does not require a restatement of or change in our consolidated financial statements for any prior interim period. We also developed a remediation plan for this material weakness which is described below.
Remediation of Material Weakness
We are committed to maintaining a strong internal control environment and implementing measures designed to help ensure that this material weakness is remediated as soon as possible. To remediate this material weakness, we have implemented controls to ensure that all inputs in our fair value calculations agree to the underlying documents and are properly reviewed. We will consider the material weakness remediated after the applicable controls operate for a sufficient period of time, and management has concluded, through testing, that the controls are operating effectively.
Changes in Internal Control over Financial Reporting
During the fiscal quarter ended June 30, 2025, other than the plan discussed above under “Remediation of Material Weakness,” there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
35
Table of Contents
Part II - Other Information
Item 1. — Legal Proceedings.
None.
Item 1A. — Risk Factors.
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K of the Company filed with the SEC on December 17, 2024, and as updated and supplemented in subsequent filings. These risk factors could materially harm our business, operating results and financial condition. Additional factors and uncertainties not currently known to us or that we currently consider immaterial also may materially adversely affect our business, financial condition or future results.
Item 2. — Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. — Defaults Upon Senior Securities.
None.
Item 4. — Mine Safety Disclosures.
Not applicable.
Item 5. — Other Information.
36
Table of Contents
Item 6. — Exhibits.
| | | | | | | | | | |||
| | | | | | Incorporated by Reference to SEC Filing | | Filed or Furnished with | ||||
Exhibit | | | | | | Exhibit | | | | | | this Form |
No. |
| Filed Exhibit Description |
| Form |
| No. |
| File No. |
| Date Filed |
| 10-Q |
3.1 | | Conformed version of Certificate of Incorporation of Applied DNA Sciences, Inc., as most recently amended by the Eighth Certificate of Amendment, effective June 2, 2025 | | S-8 | | 3.1 | | 333-2889380 | | 07/25/2025 | | |
3.2 | | Conformed version of By-Laws, as amended by the Certificate of Amendment to the By-laws, effective November 7, 2024 | | S-1 | | 3.2 | | 333-283315 | | 11/19/2024 | | |
10.1 | | Separation Agreement, dated June 16, 2025, by and between Applied DNA Sciences, Inc. and Dr. James A. Hayward | | 8-K | | 10.1 | | 001-36745 | | 06/17/2025 | | |
31.1* | | Certification of Chief Executive Officer, pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | | | | | | | | | | X |
31.2* | | Certification of Chief Financial Officer, pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | | | | | | | | | | X |
32.1** | | Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | | | | | | | | | | X |
32.2** | | Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | | | | | | | | | | X |
101 INS* | | Inline XBRL Instance Document | | | | | | | | | | X |
101 SCH* | | Inline XBRL Taxonomy Extension Schema Document | | | | | | | | | | X |
101 CAL* | | Inline XBRL Taxonomy Extension Calculation Linkbase Document | | | | | | | | | | X |
101 DEF* | | Inline XBRL Taxonomy Extension Definition Linkbase Document | | | | | | | | | | X |
101 LAB* | | Inline XBRL Extension Label Linkbase Document | | | | | | | | | | X |
104 | | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibits 101) | | | | | | | | | | X |
* Filed herewith
** Furnished herewith
Exhibits 32.1 and 32.2 are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act or the Exchange Act, except as otherwise stated in any such filing.
37
Table of Contents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Applied DNA Sciences, Inc. | |
| ||
Dated: August 14, 2025 | | /s/ JUDITH MURRAH |
| Judith Murrah | |
| Chief Executive Officer | |
| (Duly authorized officer and principal executive officer) | |
| ||
| /s/ BETH JANTZEN | |
Dated: August 14, 2025 | | Beth Jantzen, CPA |
| Chief Financial Officer | |
| (Duly authorized officer and principal financial and accounting officer) |
38
Source:
FAQ
What reverse stock splits did APDN implement in 2025?
How much did APDN record in one-time personnel-related charges in fiscal 2025?
How concentrated is APDN's revenue and receivables?
What financing or equity actions did APDN complete in the October offering?
What are near-term lease and collateral obligations disclosed?
